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Chapter 1 
 
Introduction 
 
Cellular Reprogramming to Pluripotency and Regenerative Medicine 
 
With the awarding of the Noble Prize in Physiology or Medicine to Shinya 
Yamanaka and Sir John Gurdon in 2012, an international spotlight shone on their 
pioneering work in the field of cellular reprogramming. A worldwide audience recognized 
the significance of their contribution to our understanding of the elegant and intricate 
mechanisms that underlie cellular plasticity and our ability to manipulate such 
mechanisms to achieve consistent and predictable effects (Gurdon, 1962; Gurdon and 
Melton, 2008; Gurdon et al., 1958; Takahashi and Yamanaka, 2006; Takahashi et al., 
2007; Wernig et al., 2007; Yu et al., 2007). Such work has implications in basic biology, 
biotechnology, and the field of regenerative medicine, which seeks to find ways to 
improve treatments for disease and re-growing organs to replace those that are 
damaged and/or failing. 
The major thrust of the field of regenerative medicine has been towards 
generating tissues that in a normal physiological context intrinsically lack a robust 
regenerative potential (Mao and Mooney, 2015). Such tissues remain in a somewhat 
senescent state, performing homeostatic maintenance functions but lacking the ability to 
recover, in part or wholly, from major cellular and tissue losses caused by disease or 
acute injury. Among these slowly regenerating tissues are the brain, nervous and spinal 
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tissue, and the heart, Fig 1 (Kajstura et al., 1998; Rando, 2006; Bergmann et al., 2009; 
Leri et al., 2011; Sánchez Alvarado and Yamanaka, 2014; Bergmann et al., 2015; Mao 
and Mooney, 2015).   
 
 
 
 
 
Due to the limited regenerative capacity of adult human hearts, access to human 
cardiac tissue is severely limited. Yet human heart tissue is in demand. In the 
pharmaceutical industry, high fidelity models of functional human cardiac tissue are 
needed for cardioactive drug screening, safety pharmacology, and cell therapies used 
to replace damaged tissues (Amanfu and Saucerman, 2011; Mason et al., 2011; Matsa 
et al., 2014). In academia, continuing research into the mechanisms of cardiac 
Figure 1: Regenerative capacity of human organs and tissues. A schematic 
representation of the capacity for selected organs and tissue types to regenerate. At the 
left, labeled “High”, are organs and tissues with resident stem cell niches that enable a 
very robust regenerative potential. In the case of blood cells, for example, regeneration 
can happen in as few as 24-48 hours (red blood cells). On the right, labeled “Low”, are 
organs and tissue types that have little to no regenerative capacity. The heart for instance 
has been reported to turn over (completely replace its cells) at as low a rate as 50% per 
lifetime.   Adapted from Rando, TA et. al. (2008) Stem cells, ageing and the quest for 
immortality Nature. 
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development, tissue engineering techniques, regenerative medicine, and cardiac 
disease requires access to abundant sources of human cardiac cells and tissues (Shim 
et al., 2012; Feaster et al., 2015; Dees and Baldwin, 2016; Passier et al., 2016; Ruan et 
al., 2016).   
Efforts to regenerate heart tissue have focused on first understanding the 
processes by which heart tissue forms during development, and then on mimicking this 
process in vitro where pluripotent stem cell cultures are exposed to a regimen of growth 
factors, cellular matrix substrates, and small molecules that induce differentiation of the 
cells through types representative of the primary germ layer or mesoderm, then on to 
cardiac mesoderm and finally to functional cardiomyocytes (van Berlo and Molkentin, 
2014; Mercola et al., 2011; Ruan et al., 2016; Ye et al., 2013). The remainder of this 
chapter will briefly cover cardiac development and the signaling pathways that govern it. 
Extended discussion of the TGFβ and BMP signaling pathways are included to provide 
context for the work described in Chapters 3 - 9. 
 
Cardiac Development 
While our understanding of the anatomical and morphological features of heart 
development spans more than a century, it is only recently that we have begun to 
unlock the cellular and molecular mechanisms of this amazingly complex process (Dees 
and Baldwin, 2016). 
In the post-gastrulation embryo the heart and circulatory system are the first fully 
functional organ system to form, pumping nutrient rich blood to cells within developing 
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tissues.  The adult heart is made up of several cell types.  The endocardium is a cellular 
layer lining the chambers, valves, and vessels of the heart that is primarily comprised of 
endothelial cells.  The myocardium consists of cardiomyocytes that are responsible for 
generating contractile force in the heart. Cardiomyocytes within the myocardium can be 
categorized into subtypes. Atrial myocytes are primarily responsible for regulating blood 
flow into and out of the ventricles.  Ventricular myocytes provide the contractile force 
generated during a heartbeat.  Connecting the atria and ventricles are bundles of mostly 
“non-working” cardiomyocytes that initiate and propagate the electrical signals which 
cause the heart to beat.  These non-working cells are generally referred to as 
conduction system cells. 
A fully formed heart passes through what may be described as 4 major stages of 
development: specification of early cardiac progenitors and their coalescence into 
cardiogenic regions called heart fields, fusion of these fields at the midline to form the 
heart tube, cardiac looping and primitive chamber formation, and finally cardiac 
remodeling, including septation and valve formation. 
The first of these 4 stages of heart development is the specification and migration 
of cardiac progenitor cells from the mesoderm of the gastrula.  These early cardiogenic 
regions appear around embryonic day 6.5 in mice and about 22 days post-fertilization in 
humans (Hamburger and Hamilton, 1992; Sissman, 1970).  At the earliest stages, 
cardiac progenitors are not easily distinguished from other cells in the mesoderm.  
However, by day 7.5 in the mouse these progenitors have migrated into the midline of 
the embryo to form the first distinguishable cardiac structure, the cardiac crescent 
(Harvey, 2002; Vincent and Buckingham, 2010).  At the cardiac crescent stage cardiac 
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progenitor cells reside in two distinct regions, called the primary and secondary heart 
fields (PHF and SHF, respectively) (Vincent and Buckingham, 2010).  The cells in these 
fields will become most of the heart.  Cells in the PHF become the left ventricle and a 
portion of the atria and the right ventricle.  The SHF is located lateral to the PHF and 
contributes to the remainder of the atria and right ventricle as well as the outflow tract.  
In addition to spatial regulation, the cells of the primary and secondary heart fields are 
also temporally regulated.  The cells derived from the primary heart field are the first to 
differentiate into cardiomyocytes and are known as first lineage cells.  The SHF cells 
remain in an undifferentiated state until after the PHF cells begin to form the heart tube.  
During tube formation and throughout looping, SHF cells continue to differentiate and 
make contributions to the atria, ventricles and outflow tract (Kelly, 2012).  
The second stage of heart development is cardiac tube formation.  This process 
starts around embryonic day 8 in mice and is indicated morphologically as a budlike 
structure emerges at the cranial portion in the primary heart field of the cardiac crescent 
(Harvey, 2002).  This budlike structure then enlarges as the crescent begins to fuse at 
the midline, gaining volume while expanding cranially and caudally (Buckingham et al., 
2005).  At the caudal end of the crescent PHF cells migrate downward in a bisymmetric 
fashion on the right and left sides of the emerging heart, forming an inverted Y.  At the 
top of this inverted Y the budding PHF cells, with contributions from the SHF, expand 
downward to form the heart tube. This tube is a cylindrical structure composed of 
developing myocardium on the outside and a layer of endothelium called endocardium 
on the interior. While the PHF is expanding to form the anterior portions of the emerging 
heart, the SHF is also expanding cranially and posterior to the PHF.  The cells of the 
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expanding SHF make some contribution to the mostly PHF-derived heart tube but also 
form a distinct structure at the top of the inverted Y that will eventually become the 
outflow tract.  The cranial and caudal portions of this tube are known respectively as the 
arterial and venous poles.  Once the heart tube is completely fused between the 
correctly oriented arterial and venous poles, it begins to act as a rudimentary pump.     
At this point the heart detaches itself from the mediastinum and orients itself 
properly for chamber and valve formation.  This reorientation process occurs during the 
third major stage in heart development, cardiac looping.  In mice this looping process 
begins around embryonic day 9.0 and in humans around 5 weeks post-fertilization.  In 
mice this process takes about 1-2 days to complete.  As already described, the newly 
formed heart tube is at this point an asymmetric structure consisting of a bifurcated 
region at the venous pole and a straight tube with rudimentary SHF-derived outflow tract 
at the arterial pole.  During looping the venous pole of the heart moves dorsally and 
cranially while twisting to the right, bringing it to a cranial position just above the 
developing ventricles.  While the venous pole is reorienting as described, the arterial 
pole containing the outflow tract is also moving, albeit caudally and ventrally in an 
opposite and complementary fashion.  These movements have now oriented the two 
poles in an asymmetric dorsal-ventral configuration with the outflow tract on the right 
and a common atrium and inflow tract on the left.  These two regions are connected by 
a loop of bulbous, asymmetric cardiac tissue that includes the atrioventricular (AV) 
canal.  This bulbous loop will eventually become the left and right ventricles.  The 
former poles will become the atria and major vessels located at the base of the heart  
(Buckingham et al., 2005; Harvey, 2002).   
7 
 
The final step of development is cardiac remodeling and completion of the 
cardiac chambers.  At this point the common atrium expands to form two appendages.  
While these atrial appendages are forming, the outflow tract is imposed upon their 
junction by continued spiraling of the heart tube.  The outflow tract and atria fuse, 
producing two distinct atrial chambers.  At the same time the inflow region insinuates 
itself between the bulging ventricular regions on the dorsal side of the heart.  The inflow 
tract then fuses with the cardiac loop creating separate left and right ventricles.  During 
this stage the valves and septa that separate the chambers from one another are also 
forming.  The endocardial cushions in the AV canal give rise to the tricuspid and mitral 
valves while those in the outflow tract form the septum dividing the outflow tract into the 
aorta and pulmonary artery (Harvey, 2002). 
These four steps highlight the complexity of the heart forming process.  Although 
the procession through these four stages is complete by around E14 in the mouse, the 
heart continues to grow and mature through the remaining week prior to birth and post-
natally.  For the purpose of this work, these four basic steps provide the proper context 
for our discussion of the cell types that populate the heart during development and the 
molecular mechanisms that drive their expansion and differentiation.  It is this 
understanding of molecular mechanisms that regulate heart development that has 
allowed us to generate cardiomyocytes in vitro from pluripotent stem cells. 
 
Molecular Events in Heart Development 
In order to appreciate how our understanding of the major events in 
cardiogenesis has been applied to pluripotent stem cell differentiation in vitro, it is 
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important to describe the major cell types involved in each of the developmental stages 
of the heart in terms of their origin, movements and eventual fates.  Coordinating the 
differentiation and movement of cells during the four stages outlined above are major 
developmental signaling pathways.  From mesoderm derivation to remodeling and 
chamber formation, these signaling pathways act to sequentially regulate cardiac 
transcription factor networks.  These transcription factor networks regulate specific 
structural and functional genes that eventually characterize the mature cardiac cells 
(Bruneau, 2013).  Thus the molecular and cellular events that drive cardiogenesis are 
best thought of in terms of these signaling pathways and the transcription factors under 
their control.  In the context of cardiomyocyte differentiation from pluripotent stem cells, 
signals and factors regulating the origin and differentiation of early cardiac progenitor 
cells are most relevant.   
 
Molecular Regulation of Mesoderm Specification   
Prior to gastrulation, stem cells from the inner cell mass of the blastula 
differentiate to one of the earliest embryonic tissue types, the epiblast.  Cells of the 
epiblast then give rise to the three primary germ layers.  Epiblast cells first form the 
primitive streak and the earliest of the three germ layers, the ectoderm.  The cells of the 
primitive streak then go on to form the endoderm and mesoderm.  This transition of 
embryonic stem cells towards mesodermal tissue may be classified as the first 
important transition in vivo that guides our understanding of how to generate 
cardiomyocytes in vitro from pluripotent stem cells. 
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As gastrulation progresses, epiblast cells migrate through the primitive streak 
and expand outward between the ectoderm and endoderm (Arnold and Robertson, 
2009). Mesodermal cells continue to expand laterally into the developing space 
between the ectoderm and endoderm, eventually segmenting into four different sections 
(Gilbert, Scott F., 2010).  Various signaling pathways direct the specification, migration, 
and expansion of mesoderm from epiblast through the primitive streak and into its final 
position between ectoderm and endoderm, including Activin/Nodal, Wnt, BMP and FGF 
(Arnold and Robertson, 2009; Thiery et al., 2009).    
Early induction of mesoderm is associated with the activity of Activin/Nodal 
signaling.  Nodal is expressed in the epiblast where it activates BMP signaling that in 
turn activates Wnt.  Later, Nodal and BMP act together to control the expression of Wnt 
antagonists such as Dkk1 to restrict Wnt signaling to the primitive streak, where it 
directs the formation of mesoderm.  As mesodermal tissue continues to form, Wnt 
signaling is detected towards the posterior end of the primitive streak around E6.5 and 
then expands into the entire primitive streak and much of the mesoderm by E7.5 (ten 
Berge et al., 2008).  Loss of Wnt signaling components, including Wnt ligands, co-
receptors and β-Catenin (the nuclear protein mediating Wnt transcriptional control) 
results in a failure to form mesodermal tissue (Haegel et al., 1995; Kelly et al., 2004; Liu 
et al., 1999; Takada et al., 1994; Yoshikawa et al., 1997). 
Wnt signaling affects the formation of mesoderm mainly via the Wnt ligand 
Wnt3A.  Wnt3A regulates the activation of the essential mesodermal transcription 
factors T-brachyury (T-bry) and Eomes (Yamaguchi et al., 1999).  In fact Wnt signaling 
acts directly on T-bry via translocation of β -catenin to the nucleus and activation of 
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gene transcription (Arnold et al., 2000). These transcription factors play a critical role in 
cell migration during mesoderm specification and are used as definitive markers of 
mesodermal tissue (Tam and Loebel, 2007).   
FGF signaling also plays an essential role in the early formation of mesoderm.  
Loss of FGF ligands such as FGF8 and receptors such as FGFR1 leads to a failure of 
mesoderm formation because of defective cell migration during the primitive streak 
stage (Ciruna and Rossant, 2001; Sun et al., 1999; Yamaguchi et al., 1994).  The effect 
of FGF signaling on mesoderm formation is likely mediated via its regulation of the 
transcription factors Snail, T-bry, and Tbx6, three genes required for mesoderm 
migration, specification, and patterning. 
 
Transcription Factors in Cardiac Development 
Cardiac precursors can be detected in the anterior region of the primitive streak 
during the early stages of mesoderm formation.  These early cardiac cells are present 
on either side of the embryonic midline and express the transcription factors Mesp-1 
and Mesp-2.  Loss of Mesp expression in these cells aborts migration of emerging 
cardiac progenitor cells (Bondue and Blanpain, 2010; Buckingham et al., 2005; Saga et 
al., 1996).  
Expression of Mesp-1 in the cardiogenic mesoderm is a master signal that 
induces the cardiac transcription factor signaling network (Bondue and Blanpain, 2010).    
These transcription factors include Nkx2-5, Hand2, Myocardin (Myocd), Gata4, Mef2c, 
Tbx20, FoxH1, Foxc1, SRF and Foxc2 among others (Bondue and Blanpain, 2010).  
The mechanism behind this activation lies in the ability of Mesp-1 to bind directly within 
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the regulatory regions of its target genes including Nkx2-5, Hand2 and Myocd.  Myocd 
in turn activates Mef2c and SRF, which go on to activate the essential cardiac structural 
genes Myh6, Myl1, Myl2, Myl7, and cardiac troponin 2 (Tnnt2) (Bondue et al., 2008; 
Lemonnier and Buckingham, 2004).   
  Each of the transcriptional events in the formation of cardiac progenitors is 
dependent on Mesp-1 expression beginning in the early mesoderm and persisting 
through the expression of the cardiac-specific structural and functional components that 
define mature cardiomyocytes.  Thus, cardiogenesis on a cellular level occurs via the 
carefully orchestrated, stepwise differentiation of progenitor cells towards mature 
cardiac subtypes, directed by cardiac transcription factors.  As will discuss later, it is 
upon this principle that most protocols for production of de novo cardiomyocytes from 
pluripotent stem cells depend. 
Each of these transcription factors is expressed in specific regions of the 
developing heart during particular periods of heart development and plays a distinct role 
during cardiogenesis.   
For example, Nkx2-5, Hand1 and 2, Gata4, Tbx1, 5 and 20 are expressed in the 
PHF.  These transcription factors direct the differentiation of cells within the PHF as they 
populate the heart tube and differentiate during looping morphogenesis (Buckingham et 
al., 2005; Harvey, 2002; Vincent and Buckingham, 2010).  Nkx2-5 is critical for atrial-
ventricular chamber compartmentalization and formation of ventricular tissue.  Hand1 
and 2 play a role in the formation of the left and right ventricles, respectively.  Gata4 
expression is essential for looping morphogenesis, septation of the valves and 
formation of ventricular myocardium.  At the stage of heart tube formation cardiac cells 
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must migrate and fuse at the midline.  Here, Gata4 and a companion transcription 
factor, Foxp4, are essential for proper tube formation as loss of function mutations in 
these genes lead to a failure of the cardiac fields to fuse and form a proper heart tube 
(Harvey, 2002). 
The Tbx transcription factors comprise a whole class that plays diverse roles in 
cardiogenesis.  These roles include patterning and specification of conduction system 
cells, sinoatrial nodal cells and distinguishing between atrial and ventricular 
myocardium.  In fact patterning via the Tbx genes is the major driver for distinguishing 
between working and non-working myocardium during the later stages of cardiac 
development (Evans et al., 2010). Tbx transcription factors are also critical to the 
formation of the outflow and inflow tracts and neuralization of the atrium at later stages 
of heart development (Plageman and Yutzey, 2005; Stennard and Harvey, 2005).  
Tbx20 regulates proliferation of myocardial progenitor cells during early myocardial 
expansion.  Mutant embryos lacking Tbx20 expression present a large decrease in the 
number of terminally differentiated cardiomyocytes (Cai et al., 2005).  Tbx18 is 
expressed in the extreme posterior regions of the SHF(Vincent and Buckingham, 2010).  
Cells that express Tbx18 give rise to smooth muscle, myocardium, and interventricular 
septum (Vincent and Buckingham, 2010). 
The Isl-1 transcription factor is expressed in the SHF and plays an essential role 
in many cardiac developmental processes.  Mutations that inactivate Isl-1 result in major 
cardiac defects.  These include lack of septation in the atrial and ventricular 
compartments, abnormal atria, and no outflow tract (Cai et al., 2003).  Isl-1, along with 
Gata4, can directly control the expression of Mef2c by binding a genomic enhancer 
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element upstream of its coding sequence (Dodou et al., 2004).  Incidentally, Isl-1 
expression has been detected in the PHF as well as the SHF (where it was originally 
identified), though it does not seem to be required for formation of PHF lineages (Prall 
et al., 2007).  When Isl-1 expression is knocked down in mice the PHF and its 
associated derivatives form normally (Cai et al., 2003).   
The Forkhead transcription factors (known as Fox) are also important for cardiac 
development.  Foxh1 is expressed in the anterior region of the secondary heart field and 
plays a role in formation of the outflow tract and right ventricle (Seo and Kume, 2006).  
Foxh transcription factors also play a role in regulating other transcription factors such 
as Mef2c (von Both et al., 2004).  Mef2c is involved in the formation of the outflow tract, 
inflow tract and proper development of the right ventricle (Lin et al., 1997). 
Pitx transcription factors also regulate myocardial formation.  Pitx2c expression is 
detectable throughout the left side of the SHF during early cardiogenesis and is later 
detected extensively in the ventricular and atrial myocardium.  Pitx2c is essential in the 
formation of left-right asymmetry in the heart, and loss of Pitx2c expression leads to 
right atrial isomerism and defects in ventricular maturation (Tessari et al., 2008).  Pitx2c 
also regulates the formation of left versus right atrial chambers by repression of right 
atrial identity. 
 Atrial and ventricular cells are being patterned at very early stages of cardiac 
development.  Cells in the secondary heart field that will eventually become part of the 
atria require the expression of the transcription factor Nfatc1 in order to fully develop  
(Schubert et al., 2003).  At later stages of heart development the transcription factors 
Irx4 and Hey2 are expressed in emerging ventricles and play a role in ventricular 
14 
 
myocyte formation.  In the atria the transcription factors Hey1 and Coup-TFII are 
expressed and regulate atrial myocyte formation (Evans et al., 2010; Kokubo et al., 
2007; Wu et al., 2013). 
Transcription factors not only  regulate the proliferation, patterning, differentiation 
and final maturation of cardiomyocytes and their progenitors during development, they 
are also indispensable as markers of distinct differentiation stages from progenitor 
populations and mature cardiac subtypes.  Understanding the role of transcription 
factors in tissue specific compartments allows us to track the development of 
cardiomyocytes in vitro, thereby allowing the successful translation of developmental 
paradigms into the culture dish for efficient cardiomyocyte differentiation. 
 
Major Developmental Signaling Pathways in Cardiac Development 
The timing and expression of the transcription factor networks described above is 
coordinated by major developmental signaling pathways.  Many of the same pathways 
already discussed as important for mesoderm formation also contribute to the 
differentiation and maturation of cardiac progenitors.  These pathways control diverse 
processes including the expansion of progenitor populations and differentiation of 
progenitors to myocardial cells.  TGFβ, WNT, Notch, Retinoic Acid, and Hippo signaling 
pathways all play important roles in cardiac development (Bartram et al., 2001; Cohen 
et al., 2008; Cunningham and Duester, 2015; Dobaczewski et al., 2011; Gessert and 
Kuhl, 2010; Luxán et al., 2016; Niessen and Karsan, 2008; Rhinn and Dollé, 2012; 
Singh et al., 2016; Zhou et al., 2015).  For the scope of this work, attention will be 
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focused on the prominent role played by the TGFβ super family and specifically the 
subfamily of the Bone Morphogenic Proteins (BMP). 
 
Transforming Growth Factor Beta (TGFβ) Signaling  
TGFβ is a superfamily of secreted factors that includes TGFβ, Activin/Nodal, 
Growth and Differentiation Factors (GDF), and Bone Morphogenetic Protein (BMP) 
ligands. Due to their phylogenetic similarities, BMP and GDF signaling molecules are 
commonly grouped together, with some members having both a BMP and GDF 
designation (Miyazono et al., 2005).  
TGFβ ligands bind to two types of transmembrane receptors, classified as Type I 
and Type II. Upon ligand binding, oligomerization of the type I and type II receptors 
causes activation of the receptor complex which then activates downstream effector 
molecules within the cytoplasm (Horbelt et al., 2012).  
TGFβ receptors are serine/threonine kinase receptors that span the cellular 
membrane, consisting of a single transcellular domain, an extracellular domain, and an 
intracellular cytoplasmic domain (Kitisin et al., 2007). Cystine-rich binding motifs on the 
extra-cellular domain serve as active sites for binding of TGFβ ligands to the type II 
receptor (Hinck, 2012). Upon ligand binding, conformational changes lead to 
oligomerization of type II receptors with their type I counterparts. Receptor 
oligomerization leads to transphosphorylation of the Type I receptor by the Type II 
receptor. Phosphorylated type I receptors then phosphorylate cytoplasmic signal 
transduction proteins known as Smads (Kitisin et al., 2007). Activated Smads form 
nuclear translocation complexes that regulate the transcriptional activity of downstream 
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gene targets including ID1, ID2, and ID3. TGFβ signaling is regulated by TGFβ type III 
receptors (TGFβRIII or Betaglycan), and endoglin, a transmembrane glycoprotein that 
binds with high affinity to the TGFβRI and TGFβRIII (Guerrero-Esteo et al., 2002; 
Massagué, 2012; Morén et al., 1992).   
Members of the TGFβ superfamily play important roles in heart development. 
Activin signaling directs formation of primitive streak and mesodermal cells from the 
epiblast (Kattman et al., 2011; Ladd et al., 1998). Concentration gradients of Nodal 
direct specification of nascent mesoderm towards cardiogenic mesoderm (Brennan et 
al., 2001). TGFβ receptors and ligands themselves are required for proper coronary 
artery and heart valve formation and atrioventricular cushion transformation (Brown et 
al., 1999; Clark et al., 2016; Lai et al., 2000). 
 
Bone Morphogenetic Protein (BMP) Signaling 
Among TGFβ signaling pathway family members, the BMP sub-family is the 
largest. BMP ligands consist of a series of receptor binding molecules with a conserved 
cystine-knot binding motif including BMP2, BMP4, BMP5-7, BMP10, and BMP12-14 
(Miyazono et al., 2005; Wang et al., 2014).  
BMP signaling is highly regulated and plays a role in a host of biological 
processes (Wang et al., 2014). Traditional BMP signaling regulation can occur by cell-
specific expression of selected BMP ligands, varied binding affinities for BMPRI and 
BMPRII receptors, interaction with a host of antagonists including members of the CAN 
family (GREM2 and DAN), chordin, and Noggin, (Fig 2; Balemans and Van Hul, 2002; 
Hung et al., 2012; Kattamuri et al., 2012a; Miyazono et al., 2005; Sieber et al., 2009).   
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In canonical BMP signaling, BMP ligands bind to the extracellular domain of 
transmembrane receptors. Following the common paradigm of TGFβ super family 
members, these transmembrane receptors are known as type I or type II receptors. 
While BMP ligands can bind with some affinity to a variety of TGFβ family receptors, the 
two Type I receptors BMPR-1A (also known as ALK2), and BMPR1B (also known as 
ALK6), and the type II receptor BMPR-2 are specific to BMP signaling (Miyazono et al., 
2010). Both BMPR-1 and BMPR-2 receptors exist on the cell membrane as dimers. As 
is characteristic of TGFβ signaling family members, ligand dependent oligomerization of 
receptor dimers activates the BMP signaling cascade. However an extra level of 
regulation is achieved in BMP signaling by receptor subtype selectivity among BMP 
ligands. For example, BMP6 and 7 follow the traditional TGFβ signaling paradigm 
wherein binding affinity is higher for the type II receptor. But in the case of BMP2 and 4, 
binding affinity is higher for the type I receptor (Miyazono et al., 2010). In both cases 
binding leads to receptor oligomerization and receptor transphosphorylation, however 
downstream targets can be different depending on which receptor was bound first. 
Adding to the complexity of receptor ligand interactions is the existence in some cases 
of pre-formed tetrameric receptor complexes that, when bound, are able to cause 
phosphorylation of p38 MAPK (Gilboa et al., 2000; Nohe et al., 2002).         
An additional level of signaling regulation occurs via cross-over binding of BMP 
ligands with traditional TGFβ receptors. For example, the BMP ligands BMP-2, BMP-4, 
BMP-7, and GDF-5, can all bind to the TGFΒ type III receptor (TβRIII or Betaglycan) 
with ligand binding domains and kinetics that are highly conserved when compared to 
that of TGFβ ligands (Kirkbride et al., 2008). 
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BMP can also signal through non-canonical pathways and affect a wide range of 
additional signaling pathways, including p38, JNK, and other MAP kinases (Sieber et 
al., 2009; Wang et al., 2014; Yuan et al., 2015).  
 
 
 
 
 
 
 
 
In the heart, BMP ligands and receptors are expressed in cardiac progenitor cells 
and the mature heart.  BMP factors are secreted by endoderm during gastrulation as 
mesodermal cells move towards the cardiac crescent and SHF (Lough and Sugi, 2000).  
Noggin, DAN, GREM2 
Figure 2: BMP signaling. BMP signaling is activated when ligand binding 
facilitates the formation of a heterotetrameric receptor complex. Upon complex 
formation, the type II receptor transphosphorylates the type I receptor which in 
turn phosphorylates receptor SMAD proteins. Activated SMAD proteins regulate 
transcription of target genes. BMP inhibitors such as Noggin, DAN, and GREM2 
directly bind BMP ligands, thereby preventing receptor binding and tetrameric 
complex formation. Adapted from Shore, E. M. & Kaplan, F. S. (2010) Inherited 
human diseases of heterotopic bone formation 
Nat. Rev. Rheumatol. 
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BMP2 induces the expression of Nkx2-5 in the cardiac crescent, which then directly 
interacts with the early BMP effector Smad to auto-regulate BMP2 expression in the 
SHF (Liberatore et al., 2002).  BMP expression is also important for regulating 
elongation of the linear heart tube, heart chamber formation and cushion formation as 
well as interacting with Nodal signaling to establish left-right asymmetry (van Wijk et al., 
2007).  These interactions between BMP and Nkx2-5 regulate early cardiac expansion 
by first stimulating proliferation and then limiting the number of cardiomyocytes in the 
heart tube (Prall et al., 2007).  
Specific BMPs exert pleiotropic effects on cardiac morphogenesis and 
cardiomyocyte maturation (Pater et al., 2012). BMPs 4, 5 and 10 regulate cardiac 
looping, proper outflow-tract septation, branchial-arch artery remodeling, valve 
formation, cushion remodeling, and ventricular development (Breckenridge et al., 2001; 
Chen et al., 2004; Chocron et al., 2007; Kim et al., 2001; Liu et al., 2004; McCulley et 
al., 2008).  BMP5 and 7 play a redundant role in regulating heart development as single 
knockout of either gene results in normal development while double knockout causes 
cardiac defects (Solloway and Robertson, 1999).  BMP antagonists such as Noggin are 
also necessary for cardiac development.  Mice lacking Noggin have thicker myocardium 
than wild types (Choi et al., 2007).  This phenotype could be rescued by halving the 
gene dosage of Bmp4, indicating that fine-tuning the strength, or confining the zone of 
BMP activity is required for proper cardiac development (Choi et al., 2007).    
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Chapter Summary 
The complexity of heart formation is reflected in the varied morphogenetic and 
cellular movements during heart formation as well as the transcription factors and 
developmental signaling pathways that drive them.  While further research into the 
mechanisms of myocardial subtype specification as well as cardiac maturation and 
maintenance remains to be done, our current understanding of these processes allows 
their application towards the successful generation of cardiomyocytes in vitro from 
pluripotent stem cells. 
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Chapter 2 
 
Pluripotent Stem Cells 
 
Unique Features of Pluripotent Stem Cells 
Pluripotent stem cells (PSCs) possess two unique and defining properties that 
distinguish them from other cell types.  The first is that they are self-renewing, able to 
proliferate practically indefinitely in their undifferentiated state to generate new 
pluripotent cells.  The second defining property of pluripotent stem cells is their ability to 
differentiate and form mature, specialized cell types (Mummery et al., 2012).  In contrast 
to multi-potent stem cells, whose capacity to differentiate is confined to specific 
subtypes (Wagers and Weissman, 2004; Avgustinova and Benitah, 2016), pluripotent 
stem cells have a broader differentiation potential and can give rise to most tissue-
specific cell types (Ludwig et al., 2006; Sánchez Alvarado and Yamanaka, 2014).  
These features make pluripotent stem cells a viable source for production of 
cardiomyocytes in vitro.  
 
Pluripotent Stem Cell Sources 
Pluripotent stem cells generally come from two major sources.  The first are the 
embryonic stem cells (ESCs) that are derived from the inner-cell mass of blastocysts 
prior to implantation (Yu and Thomson, 2008) . These cells are both self-renewing and 
pluripotent, able to produce all the cell types of the body.  Due to ethical issues and 
technical constraints, most early research conducted on embryonic stem cells in culture 
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was focused on those isolated from mouse embryos (Martin, 1981; Yu and Thomson, 
2008).  As technology has advanced and our ability to deal with the political and ethical 
concerns surrounding research using human embryos has evolved, research involving 
human embryonic stem cells has become less restricted, but still poses many practical 
and ethical challenges.  Research in mouse and human ES cells has identified a large 
network of transcription factors that are required for pluripotency, self-renewal and 
suppression of differentiation (Boyer et al., 2005; Loh et al., 2006).  In a seminal 
discovery by Yamanaka, it was shown that forced expression of four of these factors: 
Oct4, Klf4, Sox2 and c-Myc is sufficient to reprogram somatic, terminally differentiated 
cells to pluripotent, embryonic-like stem cells.  These reprogrammed cells, called 
induced pluripotent stem cells (iPSCs) were first derived from mouse embryonic and 
adult fibroblasts using a subset of defined factors exogenously expressed in cultured 
cells (Takahashi and Yamanaka, 2006; Wernig et al., 2007).  Shortly thereafter the 
same technique was shown to be effective at generating pluripotent stem cells from 
human adult fibroblasts (Takahashi et al., 2007; Yu et al., 2007; Park et al., 2008).  
 iPSCs have proven to be highly similar to ESCs in their ability both to self-renew 
and to differentiate to a variety of specific cell types (Boulting et al., 2011; Passier et al., 
2016).  iPSC technology offers the advantages of being both less ethically challenging 
and more patient-specific.  Patient-specific stem cells open the way for generating 
cardiac tissue from patients suffering from genetic cardiac diseases in order to study 
these diseases in vitro and eventually the creation of patient-matched tissue for 
transplantation that is resistant to immune rejection (Murry and Keller, 2008; Passier et 
al., 2016).  
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 Since the initial reprogramming protocol, various modifications have been made 
to simplify and increase the efficiency of pluripotent stem cell induction.  These methods 
include using small molecules and proteins to aid the reprogramming process, 
generating new gene expression vectors that do not require viral integration and 
modulating regulation of pluripotency (Chen et al., 2011; Esteban et al., 2010; Jia et al., 
2010; Liang et al., 2010; Okita et al., 2011; Rais et al., 2013; Yamanaka and Blau, 
2010).  These advances have made generating induced pluripotent stem cells practical 
enough to be done in a routine fashion. 
 
Maintaining Pluripotency 
Prior to differentiation, stem cells are maintained in an undifferentiated, 
pluripotent state.  Maintenance of this pluripotent state is critical for taking advantage of 
the self-renewing capacity of stem cells and for the efficient directed differentiation of 
cardiomyocytes in vitro (Ojala et al., 2012).  If pluripotent stem cells begin to 
differentiate in culture prematurely, they rapidly lose their capacity for self-renewal and 
spontaneously acquire features of differentiated cells in a more or less random fashion.  
In such a state they are not effective for use in directed differentiation.  The tendency of 
pluripotent stem cells to spontaneously differentiate in culture must be controlled until 
they are ready to be used for directed differentiation (Burridge et al., 2012). 
Both mouse and human cells have a tendency to spontaneously differentiate.  
Growth of pluripotent stem cells on feeder cells (an inactivated layer of cells that is 
unable to divide but provide extracellular matrix and secreted growth factors) such as 
fibroblasts, also used for derivation of embryonic and induced pluripotent stem cells, 
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helps to suppress premature differentiation to some degree; however, use of feeders 
introduces an undefined component to the culture system without completely eliminating 
differentiation (Xu et al., 2001).   
The discovery that the protein LIF (Leukemia Inhibitory Factor) was sufficient to 
prevent differentiation of mouse embryonic stem cells when added to the culture 
medium presented a major advancement to the field of embryonic stem cell culture 
(Niwa et al., 1998).  LIF is effective even in the absence of feeder cells and is therefore 
an essential component for the undifferentiated culture of mESCs in feeder-free 
conditions.  Culture of stem cells in the absence of feeders eliminates the variability 
associated with the undefined role they play in maintenance of pluripotency and their 
effect on the eventual fate of stem cells during differentiation (Xu et al., 2001; 
Nakagawa et al., 2014).   
It is critical to note that LIF is not sufficient to prevent spontaneous differentiation 
of cultured human pluripotent stem cells (hPSC).  In order to support the feeder-
independent culture of hPSCs more complex mixtures of defined factors have been 
developed.  These formulations are based on our understanding of the signaling 
pathways that maintain pluripotency in vivo and include a combination of ligands such 
as bFGF and TGFβ-1 (Ludwig et al., 2006; Vallier et al., 2005).  These strategies also 
employ artificial extracellular matrices such as matrigel or vitronectin in order to 
preserve pluripotency and enhance cell survival and attachment (Mummery et al., 
2012).  Feeder-free culture of human pluripotent cells in defined media allows for more 
precise control of pluripotency and differentiation (Burridge et al., 2012). 
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In summary, the unlimited proliferative capacity and broad differentiation potential 
of pluripotent stem cells are defining characteristics distinguishing them from other stem 
cell types. As will be discussed in the following section, these characteristics make them 
ideal for use as a source for cardiomyocytes in vitro. 
 
Inducing Cardiomyocyte Differentiation 
Upon induction of differentiation, cultured pluripotent stem cells proceed through 
a well ordered progression highly similar to that observed in the early stages of 
embryonic development in vivo (Schulz et al., 2009). This includes the sequential 
formation of cells with characteristics of mesodermal progenitors, mesoderm, cardiac 
mesoderm, cardiac progenitor cells, immature cardiomyocytes and finally more mature 
contracting myocytes (Burridge et al., 2012).  While differentiating cultures are not 
purely made up of cardiac cells, among cardiomyocytes the differentiation of PSCs 
recapitulates the in vivo program with such fidelity it has been used to yield valuable 
insight into the basic mechanisms driving cardiac development (ten Berge et al., 2008; 
Kattman et al., 2006, 2007; Vliet et al., 2012).   
Tracking the expression of transcription factors characteristic of pluripotent cells, 
mesoderm, cardiac progenitors and mature myocytes is an important example of how in 
vivo developmental paradigms aid in the derivation of cardiomyocytes from pluripotent 
stem cells.  Over the first few days of cardiac differentiation, gene expression patterns 
indicate that pluripotency genes are down regulated while gastrulation gene expression 
is induced.  Starting around day 2 and peaking at day 3 in mESCs and a little later in 
human stem cells the mesodermal marker T. bry is expressed, indicating the formation 
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of mesoderm (Ojala et al., 2012; Rai et al., 2011).  After day 4 in both human and 
mouse stem cells, early cardiac markers such as Mesp-1 and Nkx2-5 can be detected.  
By day 10 cardiac-specific structural genes, including the sarcomeric light and heavy 
myosin chains as well as cardiac conduction channels, are detected.  Thus pluripotent 
stem cells pass through the necessary developmental stages discussed in the first 
section of this chapter that lead to cardiomyocyte formation (Martin-Puig et al., 2008).   
In order to coax stem cells from their pluripotent state through each of these 
stages to yield cardiomyocytes, differentiation strategies typically focus on mimicking 
the in vivo differentiation process.  The earliest of these techniques relies on the 
formation of embryoid bodies (EBs): small spheres of pluripotent cells induced to form in 
droplets of cell suspension media hung on the lids of petri dishes, or forced to 
aggregate in microwells (Burridge et al., 2011; Fuegemann et al.).  The strategy behind 
using such a system is to reconstruct the spherical nature of the early post-implantation 
embryo from which pluripotent stem cells are originally derived, in order to induce the 
process of gastrulation.  In fact, differentiating EBs give rise to layers of tissue 
representative of mesoderm, endoderm and ectoderm and will eventually produce cells 
representative of all tissues of the body (Evans and Kaufman, 1981).  The EB method is 
used for the differentiation of both human and mouse pluripotent stem cells.  Its 
effectiveness in both systems and its relative scalability have made the EB method a 
popular format for induction of differentiation.  
Monolayer differentiation techniques have also been used to induce the 
differentiation of pluripotent stem cells.  These techniques have the advantage of being 
less complex, more accessible to proteins and other molecules used for cardiac 
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induction and more amenable for use in tissue engineering and other applications 
where thin films are preferable to aggregates (Burridge et al., 2014; Laflamme et al., 
2007a; Palpant et al., 2017; Shim et al., 2012; Zhang et al., 2012).  Monolayer 
differentiation does not inherently produce embryonic germ-layer tissues as do EBs.  
Thus, these protocols rely heavily on directed differentiation techniques. 
 
Directed Cardiomyogenesis 
EB formation alone is enough to induce some cardiogenesis.  After induction of 
differentiation small clusters of contracting cells are usually observed between days 8-
10 of differentiation in mESCs and a little later in hPSCs (Laflamme et al., 2007a; 
Maltsev et al., 1994; Mummery et al., 2002).  However, only a small portion of cells in 
differentiating EBs will spontaneously become cardiomyocytes, usually around 5-10% 
(Zwi et al., 2009).  Non-cardiomyocyte populations include other mesodermal lineages 
such as endothelial cells and smooth muscle cells, and those of the other germ layers 
including neurons.  Thus, merely forming EBs and allowing them to differentiate is not 
sufficient to generate large numbers of relatively pure cardiomyocytes from pluripotent 
stem cells in vitro.  As already mentioned, monolayers of PSCs also form few if any 
cardiomyocytes when simply allowed to spontaneously differentiate in culture.   
In order to generate higher percentages of cardiomyocytes, further cues from 
embryonic development are used to drive or enhance the progression of cells to form 
mesoderm, cardiac progenitors and functional cardiomyocytes.  The most effective 
current methods employ a refined approach that relies on the addition of exogenous 
factors and small molecules in defined media at precise times during the course of 
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differentiation (Burridge et al., 2012).  These factors include protein and small molecule 
agonists and antagonists of specific developmental signaling pathways including 
Activin/Nodal, Wnt, BMP, FGF, and TGFβ (Burridge et al., 2012; Mummery et al., 2012).   
The first step in directing pluripotent stem cells towards becoming 
cardiomyocytes involves the induction of mesoderm.  As discussed in chapter 1, one of 
the earliest events in the differentiation of cells to cardiomyocytes in vivo is the 
coordinated action of Activin/Nodal, BMP and FGF signaling pathways to induce 
expression of the mesodermal transcription factors T bry, Eomes and SnaiI.  Indeed 
successful protocols for the efficient induction of mesoderm include addition of the 
Nodal ligand ActivinA, the BMP ligand BMP4 and the FGF ligand FGF2 (Burridge et al., 
2012).  Once mesoderm has been formed, specification of cardiac progenitors can be 
induced using a combination of Wnt, TGFβ and BMP inhibitors with VEGF.  These 
molecules block the negative regulatory effect of their respective pathways at this stage 
of differentiation, allowing for the more robust transition of cardiac mesoderm to cardiac 
progenitor cells (Kattman et al., 2011; Yang et al., 2008a).  To drive cardiomyocyte 
differentiation from progenitor cells to functional, contracting myocytes, VEGFA, FGF2 
and the Wnt inhibitor Dkk1 are added.  As in the case of enhancing progenitor cell 
specification, these factors maintain the positive regulatory activity of VEGF and FGF 
signaling while preventing the negative regulatory effects of Wnt. 
Other molecules outside of the traditional pathway modulators have also been 
empirically determined to enhance cardiomyocyte differentiation.  These include Vitamin 
C to enhance proliferation of cardiac progenitors, cardiogenic small molecules identified 
using high-throughput screening methods, and polymers such as polyvinyl alcohol 
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(PVA) that modify surface tension (Cao et al., 2012; Elliott et al., 2011; Wu et al., 2004).  
While these molecules do not necessarily have developmental cognates, their use 
illustrates the flexibility and utility of in vitro differentiation methods for the development 
of novel approaches to increasing cardiomyocyte yields in culture. 
The most effective methods for generating monolayers of cardiomyocytes are 
those that are robust and transferrable from laboratory to laboratory. The Matrix 
Sandwich protocol, developed in the Kamp Laboratory at UW Madison, relies on both 
the stepwise differentiation of pluripotent stem cells by the timely addition of exogenous 
Activin, BMP4 and bFGF in combination with a layer of Matrigel below and above the 
cellular monolayer consistently produces high yields of cardiomyocytes (Zhang et al., 
2012). Another highly reproducible protocol is the GiWi method, which relies on the 
timely activation of wnt signaling via GSK3β inhibition (Gi) followed by wnt inhibition (Wi) 
via the addition of small molecules to the differentiation medium (Lian et al., 2013). 
These methods have been built upon to generate more refined versions that produce 
high yields of cardiomyocytes or cardiomyocytes for specialized applications (Burridge 
et al., 2014; Feaster et al., 2015).   
Despite the relatively high yield of cardiomyocytes produced using these 
protocols, there remains a significant amount of heterogeneity among the resultant 
cardiomyocytes.  Cultures often consist of other cell types, typically of the vascular 
lineage, including endothelial and fibroblast cells. Among the cardiac cells functional 
phenotypes representing ventricular, atrial, and nodal cells can be detected. This 
heterogeneity presents a challenge for practical use of pluripotent stem cell-derived 
cardiomyocytes (Lian et al., 2013).    
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The first source of heterogeneity arises from the fact that even though over 80% 
cardiomyocyte populations can be achieved by careful optimization of growth factor 
concentration and timing of treatment, the other 20% of cells are mainly mesoderm-
derived cells such as endothelial cells (Burridge et al., 2012).  Thus cardiomyocytes do 
not necessarily make up the entire population.  To address this lack of homogeneity, 
purification strategies are employed to enrich the number of cardiomyocytes present in 
the culture by either selectively eliminating unwanted cell types by inserting antibiotic 
resistant cassettes behind cardiac-specific genes, or by physically removing persistent 
cardiac progenitor cell populations using pan-vascular pre-cursor cell markers like 
kinase insert domain receptor (KDR) (Elliott et al., 2011; Kattman et al., 2011; Yang et 
al., 2008a).  Even more recently, protocols have been developed which allow 
enrichment of mature, functional cardiac myocytes using metabolic selection. Cardiac 
myocytes are unique among other cell types for their ability to metabolize lactate to 
generate ATP instead of glucose (Burridge et al., 2014; Tohyama et al., 2013). By 
completely removing glucose from the cell culture media non-cardiac cells starve and 
die out. These selection methods yield the highest purity (up to 99%) of cultured 
cardiomyocytes.  However, some of these methods carry some risk of enhanced 
tumorigenicity and are therefore most useful for applications that do not include clinical 
therapies (Burridge et al., 2012). 
Another source of heterogeneity among PSC-derived cardiomyocytes arises from 
the heterogeneous nature of cardiomyocytes themselves.  Cells of the atria, ventricles, 
nodes and conduction system have distinct functional and structural properties (Maltsev 
et al., 1994).  PSC-derived cardiomyocyte populations contain both types of working 
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myocardium as well as conduction system and nodal cells (Zhang et al., 2009).  In order 
to address this heterogeneity by directing differentiation towards specific cardiac 
subtypes, cues from development have guided development of protocols for efficient 
subtype specification.  These protocols are in the very earliest stages of research and 
remain to be fully understood, but some attempts have shown that this specification 
may be possible soon.  Modulation of signaling pathways such as retinoic acid and BMP 
can bias the differentiation of maturing cardiac cells towards specific subpopulations of 
cardiomyocytes (Kolossov et al., 2005; Wiese et al., 2011; Zhang et al., 2011).  These 
protocols remain somewhat inefficient, however, and current research into the 
mechanisms that regulate cardiomyocyte subtype differentiation is required.   
Our understanding of the signaling mechanisms that drive the development of 
cardiomyocytes in vitro continues to evolve. Still unknown are the specific roles played 
by all of the varied signaling pathways and their respective signaling molecules in this 
complex and well-coordinated process. The potential to uncover further insights into the 
mechanisms that drive cardiac subtype specification, cardiac progenitor cell expansion, 
and cardiac progenitor cell maturation is great. 
  
Chapter Summary 
 Both short and long-term applications for the use of human pluripotent stem cells 
are emerging from the state of the art.  In the short term, use of induced pluripotent 
stem cells derived from patients with traditionally intractable cardiac illnesses will allow 
large numbers of disease- and patient-specific cardiomyocytes to be generated (Itzhaki 
et al., 2011).  These myocytes can be used to study the pathology and development of 
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various cardiomyopathies in vitro, as well as to test drugs and other therapeutics for 
their efficacy as treatments.  Research into the mechanisms of long QT syndrome, for 
example, and the effect of drugs on this phenotype has already yielded insights into the 
molecular mechanisms underlying this disease (Itzhaki et al., 2011).  
Another near-term application for human pluripotent stem cell-derived 
cardiomyocytes is in toxicology and drug screening.  Most drugs that fail in late stages 
of development and clinical trials or are recalled after release cause unacceptable 
cardiac toxicity as an off-target effect (Wilke et al., 2007).  By screening drugs in a 
human cardiomyocyte model system early in the drug development process, these off-
target cardio-toxic effects can be discovered and development efforts shifted 
accordingly (Liang et al., 2013).   
In the more long-term future, hPSC-derived cardiomyocytes hold promise as a 
source of cells for regenerative therapies.  One can envision new hearts grown using 
cardiomyocytes derived from individual patient iPSCs; cardiac patches made from 
engineered myocytes on biopolymer scaffolds; and injection of engineered ventricular 
myocytes into post-ischemic tissues to replenish working myocardium (Karakikes et al., 
2015; Palpant et al., 2017).   
 Heart development is a complex process on the morphological, cellular and 
molecular levels.  Our understanding of these cellular and molecular mechanisms has 
improved greatly as molecular biology and biochemical techniques have been applied to 
elucidate the developmental signaling pathways and transcription factor networks that 
drive cardiogenesis.  This understanding has been applied to the culture and directed 
cardiac differentiation of pluripotent stem cells in vitro.  Continued research into the 
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mechanisms behind cardiomyocyte maturation and subtype specification combined with 
improved culture techniques will bring us closer to achieving the promising applications 
for pluripotent stem cell-derived cardiac myocytes. 
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Chapter 3 
  
Gremlin2/PRDC Function in Development and Cardiac Differentiation 
 
GREM2 Structure and Signaling 
Gremlin 2 (GREM2), also called Protein Related to Dan and Cerberus (PRDC), is 
a secreted BMP antagonist that belongs to a family of functionally and structurally-
related antagonists known as the CAN (Cerberus And Dan) or DAN (Differential 
screening-selected gene in neuroblastoma) family. Comprising this family are Dan (also 
known as Nbl1 and DAND1), Cerberus or Cerberus-like 1 (Cer1), SOST (Sclerostin), 
Dante (DAND5, Coco), USAG-1 (Uterine sensitization-associated gene-1 or Wise), 
Gremlin 1 (Grem1, Drm) and Gremlin2 (Avsian-Kretchmer and Hsueh, 2004; Nolan and 
Thompson, 2014a; Pearce et al., 1999).  
A defining structural feature of the DAN protein family is a cystine knot motif that 
is similar to that found in BMP ligands, that consists of 8-cystines (Nolan and 
Thompson, 2014a). Structural analysis of GREM2 shows that it is highly similar to BMP 
ligands such as BMP2 and 4 (Sudo et al., 2004). Unlike BMP ligands however, which 
form as di-sulfide linked dimers, functional GREM2 protein is a highly stable, 
noncovalent homodimer that doesn’t require disulfide bonding between cystines within 
the knot motif to stabilize its dimeric structure (Kattamuri et al., 2012a). Instead, GREM2 
dimerization is stabilized by a combination of zipper-like β-sheets at the protein core 
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and unique N-terminal α-helices that interact with one another as monomers align in an 
anti-parallel fashion (Nolan and Thompson, 2014a). These unique properties of the 
GREM2 functional dimer highlight the complexity of its structure and suggests that 
GREM2 has a distinct function among its fellow DAN family members.     
Functionally, DAN family proteins are related by their traditional identification as 
antagonists of BMP signaling through direct binding interaction with BMP ligands 
(Avsian-Kretchmer and Hsueh, 2004; Hung et al., 2012; Nolan and Thompson, 2014a). 
GREM2 selectively inhibits activation of Smad-mediated BMP signaling by BMP2, 
BMP4, BMP6, and BMP7 but has no effect on that of TGFβ, GDF9 or Activin (Sudo et 
al., 2004). GREM2 has been shown to interact directly with BMP2, BMP4, and GDF5 
(also known as BMP14) (Nolan et al., 2016; Sudo et al., 2004). Crystal structures of the 
GREM2, GDF5 complex show that GREM2 is able to directly interact with the BMPRII 
and BMPRI binding domains of GDF5, though with a higher affinity for the BMPRII 
binding domain. These structural studies also revealed that when GREM2 dimers bind 
GDF5 ligands, one GREM2 monomer remains exposed to bind another GDF5 ligand. 
This can lead to multiple, alternate binding events between GREM2 and GDF5 to form 
long protein chains. Similarly, because GREM2 binding of the BMPRII site leaves the 
BMPRI site exposed, GREM2-GDF5-BMPRI complexes are also able to form (Nolan et 
al., 2016). While other members of the DAN family have also shown to form these 
oligomeric chains, none were able to do so to such a high degree as GREM2. This 
cooperative binding strategy, wherein GREM2 combines with BMP ligands to generate 
a new oligomeric protein complex, contrasts with that of Noggin, which sequesters BMP 
ligands, completely covering their receptor binding sites (Groppe et al., 2002).  
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GREM2 Function In Vivo  
The primary sequence of GREM2 is highly conserved across many species, 
suggesting that its function has been preserved throughout evolution (Müller et al., 
2006). In mice, GREM2 expression has been detected in commissural neurons of the 
developing spinal cord and in lung mesenchyme (Lu et al., 2001; Minabe-Saegusa et 
al., 1998).  In zebrafish embryos, GREM2 expression is detected beginning around 17 
hours post fertilization (hpf) and continues through 72 hpf. It is highly expressed in the 
eye, swim bladder and in the pharyngeal arch mesoderm adjacent to the developing 
heart suggesting a role in heart development (Müller et al., 2006).  
In vivo studies using mice and zebrafish have implicated GREM2 in follicle 
development, placode neurogenesis, osteogenic differentiation and craniofacial 
patterning (Ideno et al., 2009; Kriebitz et al., 2009; Sudo et al., 2004; Zuniga et al., 
2011). Further studies in zebrafish showed that GREM2 plays a pivotal role in heart 
development. Examination of GREM2 expression by in situ hybridization shows that 
GREM2 expression domains occur in ventral pharyngeal arch mesoderm, adjacent to 
the cardiac field as cardiac progenitor cells are migrating from the midline to the left side 
of the embryo. The spatial and temporal expression of GREM2 puts it into the proper 
position to influence cardiac development from the cardiac progenitor stage through 
cardiac specification and maturation. Indeed loss of function approaches showed that 
GREM2 depletion caused randomization of the cardiac axis, varied the shape of the 
heart tube, diminished cardiac chamber volume, and resulted in incomplete looping and 
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randomized jogging (Müller et al., 2013). These defects were rescued when GREM2 
mRNA was introduced back into GREM2-deficient embryos.  
In addition to anatomical defects, loss of GREM2 resulted in reduced expression 
of the chamber-specific cardiac genes amhc and vmhc, upregulation of the laterality 
factor pitx2, and loss of lefty2, which is normally expressed on the left side of the 
embryo as the cardiac tube jogs leftward. Loss of GREM2 also resulted in an increase 
in the amount of phosphorylated Smad1/5/8 protein present in the heart. Treatment with 
the chemical BMP inhibitor dorsomorphin led to reductions in phosphorylated 
Smad1/5/8 levels and rescued loss of function mutants from cardiac chamber defects. 
These data showed that GREM2 is able to mediate cardiac development through 
modulation of BMP signaling (Müller et al., 2013). 
Over expression of GREM2 in zebrafish embryos caused an increase in the 
expression of cardiac genes and ectopic formation of cardiac tissues in the posterior 
portion of the trunk. Interestingly, this ectopic tissue was found to be entirely composed 
of atrial myocytes. The atrium was also expanded while the ventricle was significantly 
diminished. These results showed that GREM2 expression served as an atrializing 
factor and that it was necessary and sufficient for proper atrial tissue development and 
differentiation (Müller et al., 2013).   
In humans, a hypermorphic GREM2 variant, GREM2 Q76E, wherein the 
glutamine residue of normal GREM2 has been substituted for a glutamate, has been 
associated with familial atrial fibrillation (Darbar et al., 2007; Müller et al., 2013). This 
suggests that abnormal GREM2 activity can cause cardiac arrhythmias. mRNA injection 
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of the human Q76E variant resulted in slower cardiac contraction rates, abnormal atrial 
contraction velocity, and distorted wavefront propagation in zebrafish. 
Taken together these data show that GREM2 is an essential molecular 
component of proper cardiac formation. It is both necessary and sufficient in vivo to 
produce cardiac tissue, and dysfunctional GREM2 can cause human cardiac defects. 
 
GREM2 Promotes Cardiogenic Differentiation of Mouse Embryonic Stem Cells 
(mESCs) 
 The work described in the rest of this chapter investigating the role of GREM2 in 
mESCs has been published in the journal Stem Cells (Tanwar et al., 2014). As co-
author with Dr. Tanwar, I took part in experimental design, data collection, data 
analysis, figure composition, and writing the manuscript. In the following section I will 
summarize our findings. For a complete listing of author contributions please refer to 
Appendix B. 
The data discussed so far show that GREM2 is a BMP antagonist with distinct 
structural and functional properties and that it is essential for proper heart development 
in vivo. To explore the possible effect of GREM2 on promoting cardiogenic 
differentiation in vitro, mouse embryonic stem cells (mESC’s) were differentiated using 
The Embryoid Body Method and the expression pattern and effects of GREM2 
treatment were investigated (Tanwar et al., 2014).  
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 As already described, GREM2 expression can be observed in vivo early in the 
cardiac differentiation process. In mESCs, genes that are typically expressed during the 
gastrulation phase of development, such as Cerberus-like 1 (Cer1) and T-brachyury (T-
bra), are transiently induced around day 3-4 of differentiation, followed by early 
mesendoderm markers, including Bmp2, Foxf1 and Foxa2, at day 4.  These are 
followed by expression of the first hematopoietic and vascular-specific genes Gata1 and 
Vegfr2, followed by expression of the early cardiac-specific genes Nkx2.5 and 
Myocardin (Myocd).  Markers of mature cells, i.e., Hemoglobin Hbb-Y, Vascular 
Endothelial cadherin (VE-cadherin, or Cdh5), α - Myosin heavy chain (Myh6) and alpha 
Fetoprotein (Afp) are initially detected between days 5-7 (Schulz et al., 2009; Tanwar et 
al., 2014).  GREM2 expression starts around day 4 and becomes prominent from day 5 
onwards, thus appearing during the early differentiation stages of mesodermal and 
endodermal progenitor cells, marked by expression of Foxf1 and Foxa2 respectively, 
and early cardiac progenitor cells marked by Nkx2.5 and Myocd (Tanwar et al., 2014). 
Treatment of differentiating mESCs with GREM2 starting at differentiation day 4, 
when GREM2 transcripts are first detected, increased the number of cardiomyocytes in 
culture. Appearance of spontaneously contracting cells was accelerated in treated 
cultures (Fig. 3A). αMHC-DsRed mESCs, a reporter stem cell line expressing DsRed 
fluorescent protein under control of the cardiac-specific alpha-myosin heavy chain 
promoter, showed a 20-fold increase in the number of positive cells in cultures treated 
with GREM2 compared to untreated controls (Fig. 3B). And GREM2 treated cultures 
stained with antibodies recognizing the cardiac-specific α-Actinin (Fig. 3C) and Troponin 
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T2 (Tnnt2) proteins had a 20 and 120-fold increase in positive cells respectively when 
compared to control, untreated cells (Tanwar et al., 2014).   
 
 
 
 
 
 
 
 
 
 
 
RNA analysis of control (untreated) and GREM2-treated cells by quantitative 
PCR using gene-specific primers at early and late differentiation stages (day 6 and day 
10 of differentiation respectively) showed that GREM2 treatment induced both early and 
late cardiomyocyte-specific markers such as Nkx2.5 (7-fold), Gata4 (5-fold), Tnnt2 (27-
fold) and Myh6 (96-fold).  GREM2 treatment also had a statistically significant inhibitory 
effect (2-5 fold) on the expression levels of both early and late hematopoietic- (Gata1, 
Figure 3: Grem2 stimulates cardiac differentiation. CGR8 embryonic stem cells (ESCs) were allowed to form EBs 
with or without addition of Grem2 starting at differentiation day 4. (A): Grem2 accelerates the appearance (left graph) 
and expands the size of contracting areas (as percent of the total culture area) in differentiating EBs (right). **, p < .01. 
(B): CGR8 ESCs were stably engineered to express the DsRed2 fluorescent protein gene fused to a nuclear 
localization signal under the Myh6 promoter (Myh6‐DsRed) to specifically mark cardiomyocytes. Grem2 (G2) 
increases 20‐fold the yield of cells with nuclear fluorescence compared to control. Scale bar = 50 µm. **, p < .01. (C): 
Grem2 increases 120‐fold the number of α‐Actinin
+
 cardiomyocytes, quantified by flow cytometry analysis. 
Abbreviations: EB, embryoid body; Grem2, Gremlin 2; Myh6, myosin heavy chain 6. Used with permission from 
Tanwar et al., 2014. 
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Hbb-y), endothelial- (Vegfr2, CD31) and endodermal- (Foxa2, Afp) genes.  Thus 
GREM2 increased the number of cardiac myocyte cells at the expense of other 
cardiovascular and even non-mesodermal lineages (Fig. 4) (Tanwar et al., 2014).   
 
  
 
 
 
 
 
 
 
 
 
 
GREM2 treatment also had a qualitative effect on the type cardiomyocytes 
generated in treated mESC cultures. This was initially determined by the visual 
observation that GREM2 treated cultures contracted at higher rates than untreated 
cells. Because the rate of contraction is a function of the physiological properties of the 
Figure 4: Grem2 specifically expands 
cardiac differentiation. CGR8 
embryonic stem cells (ESCs) were 
allowed to differentiate untreated 
(Control, Ctrl) or treated with Grem2 (G2) 
between differentiation days 4 and 10. 
Quantitative polymerase chain reaction 
(PCR) analysis of RNA samples at day 6 
or 10 of differentiation shows induction of 
cardiac genes (Nkx2.5, Gata4, Myh6, 
Tnnt2) and decrease in the expression 
levels of hematopoietic (Gata1, Hbb‐y), 
endothelial (Vegfr2, CD31) and 
endodermal (Foxa2, Afp), as well as a 
subset of neuronal (Nestin, Tubb3) 
genes. Bars represent SE of at least 
three independent biological repeats in 
triplicates. ***, p < .001; NS, not 
significant. Abbreviations: Afp, alpha 
Fetoprotein; CD31, cluster of 
differentiation 31, or platelet endothelial 
cell adhesion molecule‐1; Foxa2, 
Forkhead box A2; G2, Gremlin 2; Gata4: 
GATA binding protein 4; Hbb‐y, 
hemoglobin Y, beta‐like embryonic chain; 
Myh6, Myosin heavy chain 6; Tnnt2, 
Troponin T type 2; Tubb3, tubulin, beta 3 
class III; Vegfr2, vascular endothelial 
growth factor receptor 2. Used with 
permission from Tanwar et al., 2014. 
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cells themselves, it was surmised that perhaps the cells had distinct electrophysiological 
properties (Maltsev et al., 1994; Mummery et al., 2002, 2012).  Isolated cardiomyocytes 
from differentiated Myh6-DsRed CGR8 cultures treated with GREM2 were subjected to 
patch-clamp electrophysiology to measure action potentials.  Untreated, control cells 
displayed a wide range of action potentials, either short, typical of atrial cells, or with a 
long plateau phase, characteristic of ventricular cells.  In contrast, GREM2-treated 
differentiating ES cells gave rise to a relatively uniform cardiomyocyte population with 
short, atrial-like, action potentials (He et al., 2003; Hescheler et al., 1997). Further 
analysis of genes typically associated with atrial cardiomyocytes showed that GREM2 
induced genes that encode atrial contractile proteins (Myl7 or Mlc2a), gap junction 
proteins (Gja5) and ion channels (Kcnj5, Cacna1d), as well as Nppa and Sarcolipin 
(Fleischmann et al., 2004; Houweling et al., 2002; Kubalak et al., 1994; Leaf et al., 
2008; Minamisawa et al., 2003; Tanwar et al., 2014; Zhang et al., 2005).   
GREM2 was able to induce cardiac differentiation and produce cardiac myocytes 
that exhibited characteristics of the atrial lineage. This induction was further found to be 
a specific property of the Gremlin subfamily of BMP antagonists. Differentiating mESCs 
treated with other BMP agonists or antagonists including BMP2, BMP4, Noggin, DAN, 
and Chordin failed to produce the same results as those observed with GREM2. 
Interestingly, Grem1, a protein closely related to GREM2 was also observed to have a 
cardiogenic effect on differentiating stem cells (Tanwar et al., 2014). 
Among BMP inhibitors tested, only GREM2 was able to promote cardiogenesis in 
treated cultures. Thus BMP antagonism likely isn’t the primary mechanism behind the 
cardiogenic effect observed in GREM2 treated cultures.  As discussed in chapter 1, 
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BMP signaling is induced when BMP ligands bind to Type II receptors, forming a 
complex that engages the Type I receptors, which subsequently undergo 
transphosphorylation by the constitutively active kinase domain of Type II receptors.  
This leads to recruitment and phosphorylation of cytoplasmic Smads 1/5/8 (P-Smads), 
which then heterodimerize with Smad4 and translocate to the nucleus, acting as 
transcriptional regulators of BMP target genes such as Id2.  Besides canonical, Smad-
mediated signaling, activated BMP receptors can also stimulate several other signaling 
cascades involving p38, JNK and other MAP kinases (Sieber et al., 2009). 
While GREM2 was able to equally antagonize canonical BMP signaling in 
mESCs when compared with other BMP antagonists, Western blot analysis of 
differentiating stem cells starting at day 4 against phospho-JNK (an indicator of non-
canonical BMP signaling activity) showed that while Noggin and GREM2 treated 
samples could inhibit Smad-mediated canonical BMP signaling (Fig. 5 A), GREM2 
treated samples had a robust upregulation of phospho JNK over the course of 96 hours 
from treatment (Fig. 5 B). This induction of JNK signaling was not observed in Noggin-
treated cells. When JNK activation was blocked in GREM2-treated differentiating 
mESCs using two structurally unrelated small molecule JNK inhibitors, the cardiogenic 
effects of GREM2 treated were abolished (Fig. 5 C, D, and E). These results showed 
that GREM2 treated cells have an increase in JNK signaling activation after treatment 
with GREM2 and that this increase in JNK signaling is required for the cardiac induction 
observed with GREM2 (Fig. 5 E) (Tanwar et al., 2014). 
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Figure 5: JNK signaling activation by Grem2 is required for atrial cardiogenesis. (A): CGR8 embryonic stem cells 
(ESCs) were allowed to differentiate untreated (Control) or treated between day 4 and 10 with Noggin (Nog) or Grem2. 
Western blot analysis of embryoid body (EB) protein lysates collected at sequential differentiation time points and 
blotted with antibodies recognizing total and phosphorylated forms of Smad1/5/8 [expected molecular weight (MW) 60 
kD] and pJNK isoforms (49 and 55 kD, respectively). Both Noggin and Grem2 effectively inhibit Smad phosphorylation. 
However, in both Noggin‐ and Grem2‐treated samples Smad phosphorylation recovers at later time points. In contrast, 
only Grem2 treatment leads to strong upregulation of JNK phosphorylation. Graphs below the blots represent 
quantification of phosphorylated Smad and JNK forms relative to total protein levels. (C, D): CGR8 ESCs were allowed 
to differentiate untreated (Control, Ctrl) or treated between days 4 and 10 with Grem2 (G2). Grem2 samples were also 
treated with the Smad1/5/8 inhibitor dorsomorphin (Dorso) and the JNK inhibitors SP600125 (SP60) and JNK
i
 V. The 
JNK inhibitors' vehicle (DMSO) was also used as a control. Quantitative polymerase chain reaction (PCR) analysis of 
Myh6 and Myl7 expression at differentiation day 10 shows that JNK inhibition suppresses Grem2‐induced cardiac and 
atrial genes, whereas dorsomorphin has no effect. Control values were arbitrarily set at 1. (E): Quantitative polymerase 
chain reaction analysis at D10 shows that JNK inhibition suppresses Grem2‐induced activation of atrial regulatory 
genes CoupTFII and Hey1. *, p < .05; **, p < .01; ***, p < .001, comparing samples as indicated by horizontal bars. 
Abbreviations: CoupTFII: COUP transcription factor 2; DMSO, dimethyl sulfoxide; Grem2, Gremlin 2; Hey1: 
hairy/enhancer‐of‐split related with YRPW motif 1; JNK, c‐Jun N‐terminal Kinase; Myh6, Myosin heavy chain 6; Myl7, 
myosin light chain 7; Nog, Noggin. Used with permission from Tanwar et al., 2014. 
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 Conclusion and Hypothesis 
The data discussed so far demonstrate that the GREM2 morphogen regulates 
proper cardiac camber formation, establishment of cardiac rhythm during embryonic 
development, and can be employed to promote differentiation of mouse ESCs to 
cardiomyocytes. The cardiogenic effect of GREM2 is unique among BMP antagonists 
and relies on an upregulation of non-canonical JNK-mediated BMP signaling activation. 
(Tanwar et al., 2014). To date all of these data represent studies conducted in non-
human model systems. While these models can yield general mechanistic insights into 
the differentiation of cardiac myocytes, in order to translate these discoveries into a 
more clinical relevant context, a human model is ideal. I hypothesized that GREM2 
plays a critical role in human cardiac differentiation and can be used as a cardiogenic 
agent in human pluripotent stem cells.    
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Chapter 4 
 
GREM2 is Expressed in Human Cardiac Progenitor Cells and Cardiac Myocytes 
 
Introduction 
 
Chapters 4-8 describe my thesis work, completed in the laboratory of Dr. Antonis 
Hatzopoulos and reported in the journal Stem Cells and Development (Bylund et al., 
2017). The text and figures from the published report have been used in chapters 4-8 
with permission from the publisher. The work reported in these chapters represents the 
contributions of a number of collaborators and colleagues. A detailed description of 
contributions is found in Appendix B. 
Expression of GREM2 in a variety of developmental contexts, and most 
importantly that of cardiac development, has already been discussed in the previous 
chapter. To date no studies have been carried out looking at GREM2 expression in the 
context of human cardiac development.  
Studies of human development in general are limited by a lack of access to 
tissues, reproductive characteristics untenable for common laboratory research, and 
important ethical considerations (Greely et al., 1989). Human pluripotent stem cells 
have been used as a proxy for studying human development in vitro (Dvash et al., 
2006). Human embryonic (ES) and induced pluripotent stem (iPS) cells differentiate to a 
variety of distinct tissue-specific cell types, providing a unique resource to study human 
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embryonic development and disease mechanisms (Bellin et al., 2012; Golos et al., 
2010; Sayed et al., 2016; Sterneckert et al., 2014).    
Thus pluripotent stem cells may be used as a model of human cardiac 
development. In order to establish a context for GREM2 expression and function in 
human cardiac development, I analyzed human pluripotent stem cells that were 
differentiated to cardiac myocytes using established cardiac differentiation protocols and 
using gene expression and immunostaining assays to investigate the pattern and cell 
specificity of GREM2 expression. 
 
MATERIALS & METHODS 
 
In situ hybridization 
Mouse E8.0 embryos were prepared and analyzed for in situ hybridization analysis 
using GREM2-specific riboprobes using standard protocols (Müller et al., 2006, 2013).  
 
Human pluripotent stem cell culture 
Human induced pluripotent stem cell lines iMR90 and DF 19-9-11 from WiCell 
were cultured under feeder free conditions in mTeSR1 or Essential 8 (E8) media (Stem 
Cell Technologies) as previously described (Beers et al., 2012).  Briefly, cells were 
thawed and seeded onto 6-well plates coated with 8.7 µg/cm2 growth factor reduced 
Matrigel (Corning) in mTeSR1 or E8 media supplemented with 10 µM Y-27632 
dihydrochloride (Tocris Bioscience) to promote cell survival and attachment.  Media was 
exchanged daily until cells reached approximately 60-70% confluence.  Cells were 
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passaged using Versene EDTA cell dissociation reagent (Thermo Fisher 
Scientific/Gibco) and seeded onto Matrigel-coated plates in mTeSR1 or E8 media 
supplemented with 10 µM Y-27632 dihydrochloride at a split ratio of 1:15 - 1:20.  Cells 
were kept in a copper-lined humidified incubator (Thermo Fisher Scientific) at 37˚C with 
a 5% CO2 atmosphere. 
 
Human embryonic stem (hES) cells WA07 were cultured in conditioned media as 
previously described (Xu et al., 2001).  Briefly, cells were cultured in mouse embryonic 
fibroblast- conditioned medium (MEF-CM) supplemented with basic fibroblast growth 
factor (bFGF) (8 ng/ml).  Cells were cultured for 4-6 days or until colonies occupied 75-
80 % of well surface area.  Cells were then passaged by rinsing with DPBS and 
incubating with collagenase (200 units/ml) for 5-10 min at 37°C to dissociate them into 
small clumps.  Clumps were then plated onto 6-well cell culture plates pre-coated with 
1ml/well of 50 µg/ml Matrigel (Corning).  Cells were kept in a copper-lined humidified 
incubator (Thermo Fisher Scientific) at 37˚C with a 5 % CO2 atmosphere. 
 
hPS cell differentiation 
Human iPS cells were differentiated using either the “Matrix Sandwich” method, 
the GiWi method, or the BMP/ACTIVIN A method as already described (Laflamme et 
al., 2007b; Lian et al., 2013; Zhang et al., 2012).  In all differentiation methods, cells 
were allowed to become 80-90 % confluent then dissociated by incubating in Versene 
EDTA cell dissociation reagent (Thermo Fisher Scientific/Gibco) for 10 min at room 
temperature.  After incubation, cells were triturated to dissociate into a single cell 
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suspension.  Single cell preparations were centrifuged for 5 min at 200 x g and cell 
pellets were re-suspended in cell culture media for plating.  
 
For the “Matrix Sandwich” method, cells were re-suspended in E8 or mTeSR1 
media (Stem Cell Technologies) supplemented with 10 µM ROCKi (Y-27632 
dihydrochloride, Tocris) and plated onto Matrigel-coated (8.7 µg/cm2) 12-well culture 
plates at a density of 500,000 cells per well.  Fresh E8 or mTeSR1 media was given 
daily until cells became 90 % confluent.  When 90 % confluent, cells were overlayed 
with 8.7 µg/cm2 growth factor reduced Matrigel (Corning) in E8 or mTeSR1 media. After 
24 hrs the matrix coating solution was removed and fresh E8 or mTeSR1 media were 
added until cells were 100 % confluent.  Cells were then treated with 1 ml/well of Day 0 
media (RPMI 1640 media supplemented with B27 minus insulin, coated with 8.7 µg/cm2 
Matrigel, and 100 ng/ml ACTIVIN A, R&D Systems).  Exactly 24 hrs later Day 0 media 
was aspirated and cells were treated with 1.5 ml/well of Day 1 media (RPMI 1640 media 
supplemented with B27 minus insulin (Life Technologies), 5 ng/ml of hBMP4 (R&D 
Systems), and 10 ng/ml hbFGF (Life Technologies).  Four days after addition of Day 1 
media, cells were treated with 1 ml/well basal differentiation media (RPMI 1640 
supplemented with B27 plus insulin).  Cells treated with GREM2 received 1 ml/well of 
RPMI 1640 media with B27 minus insulin supplemented with 150 ng/ml GREM2 exactly 
48 hrs after adding Day 1 media (day 3).  At day 5, GREM2-treated wells received basal 
differentiation medium with 150 ng/ml of GREM2.  Media in all wells was replaced daily.  
Cells were treated with similar fashion with 50 ng/ml NOGGIN or 1.5 µg/ml DAN, based 
on their specific activities (R&D Systems).  GREM2 wild-type protein and mutated 
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versions of GREM2 were synthesized, purified and measured for activity by the 
laboratory of our collaborator Dr. Thomas Thompson as previously described (Kattamuri 
et al., 2012a, 2012b; Nolan et al., 2013).    
 
The BMP/ACTIVIN A method followed the same protocol as described for the 
“Matrix Sandwich” method, but without the Matrigel overlay steps. 
 
For the GiWi method, cells were re-suspended in E8 media (Stem Cell 
Technologies) supplemented with 10 µM ROCKi (Y-27632 dihydrochloride, Tocris) and 
plated onto Matrigel-coated (8.7 µg/cm2) 12-well culture plates at a density of 500,000 
cells per well. Once cells were 100 % confluent (typically 3-4 days after seeding) 
differentiation was started by adding 2 ml/well of Day 0 media (RPMI 1640 with B27 
minus insulin and 12 µM CHIR 99021).  Exactly 24 hrs after adding Day 0 media, cells 
were treated with 2 ml/well early differentiation media (RPMI 1640 with B27 minus 
insulin).  After 48 hrs 1 ml/well of conditioned media was removed from differentiating 
cells and combined with 1 ml early differentiation media and supplemented with 2 µM 
IWR-1 endo (Tocris).  After 48 hrs, cells were treated with 2 ml/well of late differentiation 
media (RPMI 1640 with B27 plus insulin).  Late differentiation media was then replaced 
daily. 
 
Human ES cells were differentiated as previously described (Xu et al., 2011).   
Briefly, WA7 hESCs were rinsed with 2 ml DPBS and incubated with 2 ml Versene 
(EDTA, Life Technologies) for 10 min at 37°C.  Versene was aspirated and replaced 
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with 1 ml/well of mouse embryonic fibroblast conditioned media supplemented with 8 
ng/ml of bFGF.  hESCs were triturated to produce a single cell suspension and seeded 
onto 24-well Matrigel-coated (8.7 µg/cm2) plates at a density of 400,000 cells per well.  
Cells were given fresh media daily until 100 % confluent.  Once 100% confluent, cells 
were given 1 ml/well Day 0 medium (RPMI 1640 with 2% B27 minus insulin and 100 
ng/ml ACTIVIN A).  Cells were incubated at 37°C for 24 hrs and then treated with 1 
ml/well of Day 1 medium (RPMI 1640 with 2% B27 minus insulin and 10 ng/ml BMP-4).  
After 4 days, the medium was replaced with late differentiation medium (RPMI 1640 
with 2% B27).  1 ml/well fresh late differentiation media was added to each well every 
other day. 
 
Reverse Transcriptase quantitative Polymerase Chain Reaction (RT-qPCR) 
Cells were collected from each well using Tryp-LE Select (Thermo Fisher 
Scientific) and centrifuged at 200 x g for 5 min to pellet.  Cell pellets were lysed using 
RLT buffer and RNA was isolated using the RNeasy Mini Kit following the 
manufacturer’s instructions (Qiagen).  cDNA was generated by reverse transcription of 
1-3 µg of RNA as I have previously reported (Tanwar et al., 2014).  cDNA samples were 
amplified using GoTaq qPCR master mix (Promega) in a Bio-Rad CFX thermocycler.  
Relative gene expression levels were calculated using the delta-delta Ct method (Beck 
et al., 2008; Livak and Schmittgen, 2001).  Relative primer efficiencies were determined 
using the Real-time PCR Miner algorithm and confirmed experimentally using the slope 
of the standard curve from plotting log(DNA copy number) vs. Ct value (Zhao and 
Fernald, 2005).  Amplification primer sequences are reported in Table 1.   
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Immunofluorescence 
Cells were seeded onto Matrigel-coated (8.7 µg/cm2) 12-well plastic culture 
plates (Thermo Fisher Scientific) at a density of 500,000 cells per well and differentiated 
as described above for the “Matrix Sandwich” method.  Cells were fixed at the desired 
time points (differentiation days 4, 5, 6 and 10) by rinsing with 500 µl DPBS and 
incubating in 4 % PFA in PBS at 4oC for 5 min. The PFA solution was then aspirated 
and cells were rinsed with 1X PBS 5 times.  Fixed cells were permeabilized by 
incubating with 400 µl permeabilization buffer (0.2 % Triton X-100 in 1X PBS) in each 
well at room temperature for 1 hr.  Nonspecific binding was then blocked using 400 
µl/well of blocking solution (5 % non-fat dry milk in permeabilization buffer) for 2 hrs at 
room temperature with gentle rocking.  For all subsequent steps, a minimum of 350 µl of 
solution was added to each well.  Cells were then washed 3 x 5 min with 400 µl/well of 
1X PBS at room temperature. After washing, cells were incubated with primary 
antibodies in incubation buffer (0.1 % Triton X-100, 1 % BSA in 1X PBS) overnight at 
4°C with gentle rocking.  Next, cells were washed 3 x 3 min each, with PBST (0.2 % 
Tween-20 in 1X PBS) followed by 3 x 3 min each with 1X PBS.  Cells were then 
incubated with secondary antibodies diluted in incubation buffer for 1 hr at room 
temperature in the dark.  Finally, cells were then washed 2 times, 3 min each, with 1X 
PBS and stored in 400 µL 1X PBS for imaging.  
 
Imaging was done using a Leica DM IRB Inverted Microscope or a Zeiss Laser 
Scanning Microscope (LSM 880).  Image analysis and volume rendering were done 
using NIS Elements, Zen, ImageJ/FIJI, and Imaris software suites.  Primary antibodies 
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recognizing NKX2.5 (Santa Cruz Biotechnology, sc-8697, 1:50), GREM2 (ProteinTech, 
13892-1-AP, 1:100), and α-ACTININ (Sigma, A7811, 1:500) were applied.  I have also 
tested anti-GREM2 rabbit polyclonal antibodies from GeneTex (GTX108414), Abcam 
(ab102563) and R&D Systems (AF2069) at 1:100 dilution.  The fluorescent dye 4’,6-
diamidino-2-phenylindole (DAPI; Invitrogen) was added during the final 15 mins of 
secondary incubation at a 1:10,000 dilution to stain nuclei. 
 
RESULTS 
 
GREM2 is expressed in differentiating human pluripotent stem cells during 
cardiac progenitor cell expansion and differentiation 
We have previously shown that GREM2 expression in zebrafish embryos first 
appears within pharyngeal arch mesoderm, adjacent to the cardiac field, during the 
early stages of heart tube formation (Müller et al., 2006, 2013).  To test whether this 
expression is conserved in mouse embryos, I performed in situ hybridization analysis 
during the early stages of cardiac development. I found that GREM2 expression 
appears around embryonic day 8 and overlaps with the nascent cardiac field area [Fig. 
6, (Tanwar et al., 2014)]. These data are consistent with those observed in zebrafish, 
with GREM2 appearing at a similar developmental stage and embryonic area. 
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To determine whether GREM2 is associated with early human cardiac 
development, I cultured and differentiated the human induced pluripotent stem cell line 
DF 19-9-11 using the “Matrix Sandwich” method that was designed for efficient 
cardiomyocyte differentiation (Zhang et al., 2012).  I then isolated RNA samples at 
consecutive days of differentiation and analyzed the temporal program of cardiogenic 
development by RT-qPCR.  As shown in Fig. 7, expression of the T BRY gene that 
marks mesoderm formation is transiently induced at days 2-3 after initiation of 
differentiation, followed by sequential expression of markers specific to early 
cardiogenic mesoderm (MESP-1), cardiac progenitor cells (NKX2.5, ISL1, and KDR or 
VEGFR2), and cardiomyocytes (TNNT2, MYH6).   Expression of endothelial and 
hematopoietic genes (CD31, VE-CADHERIN, HBBY) were at low levels (data not 
Figure 6: In situ hybridization analysis of E8.0 mouse embryos 
using anti‐sense (left) and sense (right) Grem2 riboprobes shows 
Grem2 expression in the cardiac field area (arrow). 
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shown), likely because the “Matrix Sandwich” method is optimized specifically for 
cardiac differentiation. 
 
 
 
 
 
 
 
 
 
GREM2 expression in the context of BMP signaling components 
To place GREM2 expression in the context of other BMP signaling components 
during hiPS cell differentiation, I analyzed expression of select BMP ligands, BMP 
receptors and BMP antagonists.  Our results show that CERBERUS LIKE 1 and 
CHORDIN are transiently induced during mesoderm formation, in accordance with their 
Figure 7: GREM2 expression during human iPS cell cardiac differentiation 
follows the expression pattern of cardiac-specific genes.   RT-qPCR gene 
expression analysis in DF 19-9-11 human induced pluripotent stem (iPS) cells during 
cardiac differentiation [day 0 (D0) to day 10 (D10)] using the “Matrix Sandwich” 
method indicates cardiogenic mesoderm specification (MESP-1) and the appearance 
of cardiovascular progenitor cell gene markers (KDR, NKX2.5, ISL1).   GREM2 
expression appears concurrently with cardiovascular progenitor cells and increases 
during differentiation to cardiomyocytes marked by TNNT2, and MYH6 genes. N= 3 
replicates per condition. Abbreviations: GREM2: GREMLIN 2; ISL-1: INSULIN GENE 
ENHANCER PROTEIN 1; KDR: KINASE INSERT DOMAIN RECEPTOR; MESP-1: 
MESODERM POSTERIOR bHLH TRANSCRIPTION FACTOR 1; MYH6: MYOSIN 
HEAVY CHAIN 6; NKX2.5: NK2 HOMEOBOX 5; T-BRY: T-BRACHYURY; TNNT2: 
CARDIAC TROPONIN T 2. 
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expression patterns in other species (Biben et al., 1998; Hsu et al., 1998; Sasai et al., 
1994; Tanwar et al., 2014). I also found that NOGGIN is expressed at later time points 
of differentiation.  GREM2 expression appears after mesoderm formation, coincidently 
with early cardiac markers such as NKX2.5, and continues to rise during cardiac 
differentiation (Fig. 8).  The expression of BMP2 and BMP4 are consistent with their 
respective roles in cardiac differentiation in mice, with BMP2 being expressed first 
during cardiogenic specification, and followed by BMP4 (Ma et al., 2005; McCulley et 
al., 2008).  In contrast to the dynamic expression of BMP ligands and BMP antagonists 
during cardiac differentiation, BMP receptors (BMPR2, ALK3, ALK6) appear to be 
expressed at constant levels throughout the differentiation process.  
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GREM2 expression pattern is consistent across stem cell lines and differentiation 
protocols  
A similar expression pattern for GREM2 was also observed in 1) the WA07 
human embryonic stem cells and 2) the independently reprogrammed human induced 
pluripotent stem cell line iMR90 C4 (Fig. 9).  Furthermore, because the “Matrix 
Sandwich” method of cardiac cell differentiation depends on timely activation and 
withdrawal of BMP signaling, which may influence expression of BMP ligands and 
Figure 8: GREM2 expression during human iPS cell cardiac differentiation in the 
context of BMP signaling.   The expression pattern of BMP ligands BMP2 & BMP4, 
BMP antagonists CERBERUS-LIKE 1 and NOGGIN, as well as BMP receptors type 2 
(BMPR2) and type 1 (ALK3 and ALK6) are indicated. N= 3 replicates per condition. 
Abbreviations: ALK3 or 6:  ACTIVIN A RECEPTOR TYPE II-LIKE KINASE 3 or 6, 
also BMPR1A or BMPR1B; BMP2 or 4: BONE MORPHOGENETIC PROTEIN 2 or 4; 
BMPR2: BONE MORPHOGENETIC PROTEIN RECEPTOR 2; GREM2: GREMLIN 2. 
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antagonists, I used the distinct GiWi differentiation protocol that relies on sequential 
activation and inhibition of canonical Wnt signaling (Lian et al., 2013).  The results show  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: GREM2 expression pattern during cardiac differentiation is conserved among 
pluripotent stem cell lines and independent of differentiation method.  RT-qPCR analysis of 
GREM2, T-BRY, KDR, NKX2.5 and TNNT2 genes at distinct differentiation time points from day 0 
(D0) as indicated.  (A) Gene expression during differentiation of human iMR90-C4 iPS cells.  (B) 
Gene expression during differentiation of human embryonic stem (hES) cells WA07.  (C) Gene 
expression during differentiation of DF 19-9-11 human iPS cells using the small-molecule Wnt 
modulation or GiWi method.  N=3 replicates per condition. 
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a similar induction profile of GREM2 during cardiac differentiation following the 
GiWi protocol, indicating that the GREM2 expression pattern is independent of the 
differentiation method used or the pluripotent cell line used for differentiation (Fig. 9).   
Taken together, my data demonstrate that GREM2 expression starts after 
mesoderm formation, during the initial phase of cardiac progenitor cell (CPC) 
specification, and is retained throughout CPC expansion and differentiation to 
cardiomyocytes.  The GREM2 expression pattern is unique among BMP antagonists, 
although NOGGIN is also expressed within specific time windows of cardiac 
differentiation.   The GREM2 expression pattern is consistent with our previous studies 
in zebrafish and mouse development, as well as mouse ES cells differentiation (Müller 
et al., 2006, 2013; Tanwar et al., 2014), indicating that GREM2 expression, and possibly 
function, have been conserved during evolution from lower vertebrates to humans.   
Furthermore, the GREM2 expression pattern is consistent among different human ES 
and iPS cell lines and independent of the applied differentiation protocol, suggesting 
GREM2 expression during early cardiac differentiation in hiPSCs is conserved and not 
cell-line or protocol dependent. 
 
GREM2 is expressed in human cardiac progenitor cells and differentiated 
cardiomyocytes 
To determine the cellular source of GREM2, I performed immunofluorescence 
(IF) staining on fixed cells during early (day 5 and 7) and late (day 10) differentiation 
stages using primary antibodies against GREM2, and antibodies recognizing typical 
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cardiac-specific proteins, such as the transcription factor NKX2.5 and the sarcomeric 
component α-ACTININ.  
To identify antibodies specific for detection of human GREM2 protein in cultured 
cells, I screened four distinct, commercially available, anti-GREM2 primary antibodies.  
To this end, I used HEK 293 cells transiently transfected with a plasmid expressing the 
human GREM2 cDNA under the regulation of the CMV promoter, or empty vector as 
control.  Transfected cells were fixed, stained, and imaged using a fluorescence 
microscope (Fig. 10).  Three antibodies were observed to have a GREM2-specific 
signal. Among these antibodies, signal strength was observed using fluorescent 
microscopy and the antibody that generated the highest contrast between true signal 
and background was subsequently selected for immunolabeling of differentiating iPS 
cells. 
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I found that GREM2 is expressed in NKX2.5+ cells at differentiation day 5 (Fig 
7A). This expression continued through differentiation day 7 (Fig. 12 B).  GREM2 
protein expression persists in α-ACTININ+ cardiomyocytes at day 10 of differentiation 
(Fig. 11 B and Fig. 12 C).  GREM2 was not detected in NKX2.5- cells, suggesting 
GREM2 expression is confined to the cardiac lineage during iPS cell differentiation and 
acts in autocrine fashion.   
 
 
Figure 10: Specificity and robustness screen of available antibodies recognizing 
human GREM2 protein.  Plasmid constructs containing the coding region of the human 
GREM2 gene under the CMV promoter (CMV-hG2) and empty vector (EV) as control were 
used for transfection of human embryonic kidney (HEK293) cells.   Four distinct antibodies 
against GREM2 from different commercial sources were used to immunostain transfected 
HEK293 cells.   Antibody A, rabbit polyclonal Grem2 antibody (ProteinTech, 13892-1-AP) 
gave the best noise to signal ratio and was used in subsequent staining experiments.  The 
remaining anti-GREM2 antibodies tested were rabbit polyclonal antibodies from GeneTex 
(Cat# GTX108414), Abcam (ab102563) and R&D Systems (AF2069). 
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Figure 11: GREM2 is expressed in cardiac progenitor cells and 
cardiomyocytes.  Immunofluorescence analysis of differentiating human iPS 
cells.  (A) Cardiac progenitor cells at differentiation day 5, marked with NKX2.5 
(red), express GREM2 (green). White arrows mark NKX2.5- cells that also lack 
GREM2 expression (upper panels). Scale bar, 30 μm.  3-D reconstruction using 
z-stack confocal microscopy images illustrates GREM2 expression in NKX2.5+ 
cells (lower panels).  Scale bar, 30 μm.   (B) Differentiated cardiomyocytes at 
differentiation day 10, marked with α-ACTININ (red) express GREM2 (green; 
upper panels).  Scale bar, 30 μm.  3-D reconstruction of confocal microscopy 
images (lower panels) shows GREM2 expression in differentiated cardiomyocytes 
with sarcomeric structures.  Scale bar, 20 μm.  DAPI staining (blue) marks cell 
nuclei.  Abbreviations: ACTN2: α-ACTININ. 
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Figure 12: Low magnification (20X) images show extent of GREM2 expression in 
hiPSCs.   Immunofluorescence analysis of differentiating human DF 19-9-11 iPS cells.   
(A) Low magnification images of iPS cells at differentiation day 5 using the “Matrix 
Sandwich” method showing GREM2 (green) expression in NKX2.5+ (red) cardiac 
progenitor cells (top panels).  3-D reconstruction of confocal microscopy images (lower 
panels) shows GREM2 expression in the cytoplasm and pericellular areas of NKX2.5+ 
cardiac progenitor cells.  Scale bar, top 100 μm; bottom 50 μm.  (B) Low magnification 
images of iPS cells at differentiation day 7 using the “Matrix Sandwich” method showing 
GREM2 expression persists in differentiating NKX2.5+ cardiac cells.  Scale bar, 100 μm.  
(C) Low magnification images of iPS cells at differentiation day 10 using the “Matrix 
Sandwich” method shows the extent of GREM2 expression in α-ACTININ+ 
cardiomyocytes.  Scale bar, 100 μm.  DAPI staining (blue) marks cell nuclei. 
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Summary 
Pluripotent stem cells follow a well ordered progression of transition states from 
their naïve pluripotent state towards cardiomyocytes. This process can be tracked using 
marker genes and proteins that are characteristic of distinct functional cell types. 
The immunofluorescence data described above indicate that GREM2 is present in 
the cytoplasm of cardiac progenitor cells and maturing cardiomyocytes. GREM2 is a 
secreted protein (Hsu et al., 1998).  It is possible that the GREM2 labeling observed in 
the cells reflects production of GREM2 within the cytoplasm that is being trafficked to the 
membrane for secretion. Presence of secreted protein is difficult to detect using 
immunofluorescence techniques. Future experiments involving crosslinking and then 
immunolabeling of differentiating cultured hiPSCs could provide clarification.  
Using human pluripotent stem cells I have shown that GREM2 is expressed during 
human cardiac differentiation. This expression begins as cardiac progenitor cells are 
being specified and continues through cardiac differentiation as cells transition to 
functional cardiac myocytes. This expression pattern is not unique to a single cell line nor 
is it unique to a single differentiation protocol. The consistent nature of GREM2 
expression among protocols and the timing of its expression during cardiogenesis 
suggest that GREM2 function is conserved and that it plays a role in human cardiac 
differentiation. 
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Chapter 5 
 
BMP Signaling Inhibition is Required for Cardiomyocyte Differentiation 
 
Introduction 
 
BMP2 is a prototypical dimeric BMP ligand and initiates canonical BMP signaling 
via high affinity binding to BMPRI receptors via a so called “wrist” epitope, a central 
alpha helical arrangement within the BMP2 homodimer (Kirsch et al., 2000). Once 
bound to BMPRI the BMPRI:BMP2 complex is then able to bind BMPRII via a “knuckle” 
region, a smaller, lower affinity epitope comprised of five beta sheets (Kirsch et al., 
2000).  
BMP2 is regulated by modulator proteins that directly bind the BMP2 homodimer 
and interfere with its ability to bind BMPRI and/or BMPRII (Keller et al., 2004). These 
proteins include Noggin and members of the CAN/DAN family including GREM2 (Nolan 
et al., 2016). These modulator proteins bind with high affinity directly to the wrist and/or 
knuckle regions of BMP homodimers thereby blocking the ability of BMP ligands to 
interact with either of their BMPR partners (Keller et al., 2004; Zhu et al., 2006). 
L51R is a mutant BMP2 ligand that has a substitution of arginine for leucine at 
position 51 which renders it unable to bind BMPRs and activate BMP signaling but 
retains its ability to bind BMP modulators such as Noggin (Albers et al., 2012). Addition 
of excess amounts of L51R to cultured cells effectively sequesters BMP antagonists by 
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competing for binding with endogenous, wild-type BMP molecules (Albers et al., 2012). 
This makes it an effective tool for studying the role of BMP antagonism in vitro.  
GREM2 is known to inhibit canonical BMP signaling, and the spatial and 
temporal expression data described above suggest it may play a role in cardiac 
differentiation. These data also show that the BMP inhibitor Noggin is expressed during 
cardiomyocyte differentiation. These data suggest that BMP inhibition may play a role in 
human cardiac differentiation, though it is not known if BMP inhibition is necessary for 
proper human cardiomyocyte differentiation. To investigate the role of BMP inhibition in 
human cardiac differentiation I tested the ability of the L51P mutant to interfere with 
GREM2-mediated inhibition of BMP signaling. L51P was then used to treat 
differentiating human induced pluripotent stem cells to determine if BMP inhibition is 
required for proper human cardiomyocyte differentiation.  
 
Materials and Methods 
 
Human pluripotent stem cell culture 
Human induced pluripotent stem cell lines iMR90 and DF 19-9-11 from WiCell were 
cultured under feeder free conditions as described in Chapter 4. 
 
iPS cell differentiation 
Human iPS cells were differentiated using the “Matrix Sandwich” method as described 
in Chapter 4. Cells were treated with L51P decoy protein starting at day 4 of 
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differentiation. The L51P decoy was provided by our collaborators in the lab of Dr. Thom 
Thompson at the University of Cincinatti. 
 
Reverse Transcriptase quantitative Polymerase Chain Reaction (RT-qPCR) 
Cells were collected from each well using Tryp-LE Select (Thermo Fisher Scientific) and 
centrifuged at 200 x g for 5 min to pellet.  Cell pellets were lysed using RLT buffer and 
RNA was isolated using the RNeasy Mini Kit following the manufacturer’s instructions 
(Qiagen).  cDNA was generated by reverse transcription of 1-3 µg of RNA as I have 
previously reported (Tanwar et al., 2014).  cDNA samples were amplified using GoTaq 
qPCR master mix (Promega) in a Bio-Rad CFX thermocycler.  Relative gene expression 
levels were calculated using the delta-delta Ct method (Beck et al., 2008; Livak and 
Schmittgen, 2001).  Relative primer efficiencies were determined using the Real-time 
PCR Miner algorithm and confirmed experimentally using the slope of the standard 
curve from plotting log(DNA copy number) vs. Ct value (Zhao and Fernald, 2005).  
Amplification primer sequences are reported in Table 1.   
 
Cell quantification 
Cells were dissociated into single cell suspensions using Tryp-LE Express (Life 
Technologies), stained with trypan blue (diluted 1:2 in PBS or cell culture media) to 
exclude dead cells and quantified using a Bio-Rad TC-10 automated cell counter.  For 
DAPI stained cells, cell numbers were quantified by dividing 3 fields of view from three 
independent wells per condition into quadrants and manually counting the number of 
nuclei visible in each quadrant. 
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Luciferase assays 
CGR8 mouse embryonic stem (ES) cells were transfected with the BRE2-Luc 
reporter construct with luciferase expression under the control of two canonical BMP 
signaling responsive elements of the Id2 gene (Monteiro et al., 2004; Tanwar et al., 
2014).  Cells were treated for 8 hrs with 40 ng/ml BMP4, 50 ng/ml GREM2, and/or 300 
ng/ml BMP decoy protein L51P (Albers et al., 2012).  Firefly luciferase activity was 
normalized to Renilla luciferase activity to account for transfection efficiency. 
 
Results 
 
Titration of GREM2 concentrations for effective inhibition of canonical BMP 
signaling 
The GREM2 expression data described above suggest that BMP signaling 
antagonism is necessary for cardiomyocyte differentiation.  To test this possibility, I 
treated differentiating iPS cells with a L51P mutant of BMP2 that was shown to bind the 
BMP antagonist NOGGIN, but unable to al bind BMPRI and activate BMP signaling, 
thus acting as a BMP ligand decoy (Albers et., 2012).  To test the ability of the BMP 
decoy to block GREM2, I first transfected CGR8 mouse Embryonic Stem (ES) cells with 
a plasmid containing the firefly luciferase gene under the control of the BMP-signaling 
response elements from the Id2 gene promoter [BRE2-Luc, (Monteiro et al., 2004; 
Tanwar et al., 2014)].   Optimal concentrations for effective BMP signaling inhibition by 
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GREM2 were first determined by titrating increasing concentrations of GREM2 in cells 
exposed to a constant amount of BMP4 (Fig. 13).   
 
 
 
BMP decoy L51P effectively blocks GREM2 mediated inhibition of BMP signaling 
The cells were then treated with BMP4, GREM2, and/or the BMP decoy.  The 
results show that BMP4 induces canonical BMP (BRE2-Luc) signaling, whereas the 
BMP decoy alone does not signal nor does interfere with BMP4 signaling activation 
Figure 13: GREM2 protein titration of BMP signaling inhibition.   
Mouse embryonic stem cells were transfected with the BRE2-Luc reporter 
construct and treated for 8 hrs with 40 ng/ml BMP4 and decreasing 
concentrations of GREM2 as indicated.   50 ng/ml (or higher 
concentrations) of GREM2 completely inhibited canonical BMP signaling 
activated by BMP4. N = 3. 
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(Fig. 14).   GREM2 inhibits BMP4 activity, where GREM2 alone does not induce BRE2-
Luc activity, as expected.   Moreover, co-incubation of BMP4, GREM2 and the BMP 
decoy restored canonical BMP signaling, indicating that the BMP decoy effectively 
blocks the inhibitory effect of GREM2 (Fig. 14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: BMP decoys block the inhibitory effects of GREM2.  Mouse 
embryonic stem (ES) cells were transfected with the BRE2-Luc reporter construct 
with luciferase expression under the control of two canonical BMP signaling 
responsive elements of the Id2 gene.  Cells were treated for 8 hrs with BMP4, 
[GREM2], and the [L51P] BMP2 decoy in various combinations as indicated.  In 
the presence of the BMP decoy, GREM2 inhibition of BMP signaling is aborted.  
One-way ANOVA with Dunnett’s test was performed to compare the 
experimental groups to the no treatment control group. N = 3 replicates per 
condition,  ***P < 0.001. Error bars represent std dev. 
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BMP inhibition is required for human pluripotent stem cell cardiac differentiation  
Treatment of differentiating human pluripotent stem cells with the BMP decoy 
protein starting at day 4 of differentiation, when cardiac progenitor cells (CPCs) first 
appear and GREM2 expression is induced, caused a significant reduction in cardiac 
gene expression levels and reduced the percentage of contracting cells in culture (Fig. 
15A and B respectively).   
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 15: BMP ligand antagonism is required for cardiac differentiation of 
human iPS cells.   (A) RT-qPCR gene expression analysis of RNA samples 
isolated from DF 19-9-11 iPS cells at day 7 and 10 of differentiation with or 
without BMP decoy treatment shows a reduction in cardiac gene expression in 
samples treated with the BMP decoy.  N=3 replicates per condition.  Student’s t 
test.  *P < 0.05; **P < 0.01. (B) iPS cells treated with the BMP decoy BMP have a 
significant reduction in the percentage of contracting cells at differentiation day 
10.  N=3 replicates per condition.  Student’s t test. ***P < 0.001. Error bars 
represent standard deviation. 
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Summary 
 
 Here I used the BMP mutant L51P to investigate the importance of BMP 
signaling inhibition in the cardiac differentiation process. I showed that when GREM2 is 
added in combination with an excess of L51P to BMP reporter stem cells then GREM2 
is unable to effectively block BMP signaling. This was also observed for the BMP 
antagonist Noggin, indicating that an excess of L51P can effectively sequester GREM2 
and other BMP antagonists (Albers et al., 2012).  
I further showed that when L51P was added in excess to differentiating human 
pluripotent stem cells it was able to reduce the total expression of the cardiac gene 
NKX2.5 during early and late cardiac differentiation time points (days 7 and 10 
respectively). Adding the BMP inhibitor sequestration mutant L51P to the differentiating 
cells also reduced the total percentage of cardiomyocytes in culture when compared to 
untreated controls. This reduction was consistent and significant. These data suggest 
that BMP inhibitors such as GREM2 are required for cardiac differentiation in human 
pluripotent stem cells.  
These results indicate that BMP inhibition is required and that GREM2 mediated 
inhibition may be necessary for proper cardiac function. However, the system described 
cannot distinguish between GREM2 and other inhibitors. Based on the qPCR data 
described in chapter 4, Noggin is the only other inhibitor tested whose expression is 
timed in such a way as to be involved in the cardiac differentiation process (Fig. 8). This 
would be consistent with knock-out studies in mice showing that Noggin is required for 
proper cardiac differentiation (Choi et al., 2007).  
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Future studies that directly test the necessity of GREM2 and Noggin for proper 
human cardiac differentiation are required. Emerging gene targeting strategies such as 
CRISPR have shown promise for conducting loss of function studies in human 
pluripotent stem cells (Hockemeyer and Jaenisch, 2016). Neutralizing antibodies that 
recognize and sequester GREM2 could also be used to directly test the necessity of 
GREM2 for cardiac differentiation. Among the currently available anitbodies tested for 
this purpose, none were able to neutralize GREM2. 
Another way to directly test the effect of GREM2 on cardiac differentiation is to 
use gain of function assays. Treating differentiating cells with exogenous GREM2 at 
critical time points will reveal whether GREM2 is sufficient to affect human cardiac 
differentiation. This approach is described in the following chapter. 
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Chapter 6 
 
GREM2 Enhances Cardiac Differentiation of Human Induced Pluripotent Stem 
Cells 
 
Introduction 
 
 So far I have shown that GREM2 is expressed during cardiac differentiation as 
cardiac progenitor cells are forming and then continues as progenitor cells differentiate 
to mature cardiac myocytes. The data already described above suggest that GREM2 
and Noggin may play a critical role in the human cardiomyocyte differentiation process. 
However a more direct examination of the role of these two inhibitors is required. 
 In order to test the hypothesis that GREM2 is able to enhance cardiac 
differentiation, I differentiated human induced pluripotent stem cells and tested the 
effect of purified GREM2 protein starting at differentiation day 3, as cardiac progenitor 
cells are beginning to form and when endogenous GREM2 expression is detected. 
Specifically, I examined the effect of GREM2 addition on the amounts of 
cardiomyocytes present in culture, both in total and as a percentage, and the 
expression of cardiac specific genes. GREM2 mutants with variable BMP binding 
affinities were also used to investigate whether GREM2-BMP interaction is required for 
any cardiogenic effect seen. I further tested the effect of GREM2 treatment in an 
independent human pluripotent stem cell line to verify that the effects of GREM2 
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treatment were not cell line dependent but applied more generally to cardiac 
differentiation.  
 
Materials and Methods 
 
Human pluripotent stem cell culture 
Human induced pluripotent stem cell lines iMR90 and DF 19-9-11 from WiCell were 
cultured under feeder free conditions in mTeSR1 or Essential 8 (E8) media (Stem Cell 
Technologies) as already described in Chapter 3. 
 
iPS cell differentiation 
Human iPS cells were differentiated using the “Matrix Sandwich” method as described 
in chapter 3. Cells treated with GREM2 received 1 ml/well of RPMI 1640 media with 
B27 minus insulin supplemented with 150 ng/ml GREM2 exactly 48 hrs after adding 
Day 1 media (day 3).  At day 5, GREM2-treated wells received basal differentiation 
medium with 150 ng/ml of GREM2.  Media in all wells was replaced daily.  Cells were 
treated with similar fashion with 50 ng/ml NOGGIN or 1.5 µg/ml DAN, based on their 
specific activities (R&D Systems).  GREM2 wild-type protein and mutated versions of 
GREM2 were synthesized, purified and measured for activity as previously described 
(Kattamuri et al., 2012b, 2012a; Nolan et al., 2013).    
 
Reverse Transcriptase quantitative Polymerase Chain Reaction (RT-qPCR) 
Cells were collected from each well using Tryp-LE Select (Thermo Fisher Scientific) and 
centrifuged at 200 x g for 5 min to pellet.  Cell pellets were lysed using RLT buffer and 
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RNA was isolated using the RNeasy Mini Kit following the manufacturer’s instructions 
(Qiagen).  cDNA was generated by reverse transcription of 1-3 µg of RNA as I have 
previously reported (Tanwar et al., 2014).  cDNA samples were amplified using GoTaq 
qPCR master mix (Promega) in a Bio-Rad CFX thermocycler.  Relative gene expression 
levels were calculated using the delta-delta Ct method (Beck et al., 2008; Livak and 
Schmittgen, 2001).  Relative primer efficiencies were determined using the Real-time 
PCR Miner algorithm and confirmed experimentally using the slope of the standard 
curve from plotting log(DNA copy number) vs. Ct value (Zhao and Fernald, 2005).  
Amplification primer sequences are reported in Supplementary Table S1.   
 
Cell quantification 
Cells were dissociated into single cell suspensions using Tryp-LE Express (Life 
Technologies), stained with trypan blue (diluted 1:2 in PBS or cell culture media) to 
exclude dead cells and quantified using a Bio-Rad TC-10 automated cell counter.  For 
DAPI stained cells, cell numbers were quantified by dividing 3 fields of view from three 
independent wells per condition into quadrants and manually counting the number of 
nuclei visible in each quadrant. 
 
Flow cytometry 
Differentiated human iPS cells were washed once with DPBS minus Mg2+ and Ca2+, 
incubated with 1 ml/well Accutase at room temperature for 15 mins, and triturated to 
break up into single cells.  Accutase was diluted by adding two volumes of late 
differentiation medium per well and contents were transferred to 15 ml conical tubes 
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through mesh strainer caps to remove large cell clumps.  Prior to centrifugation, and 
after visual confirmation of complete cell detachment and single cell dissociation with 
Accutase, the total cell number per well was quantified using the Bio-Rad TC-10 
automated cell counter as described above.  Cell suspensions were then centrifuged at 
200 x g for 5 min to pellet cells.  Cell pellets were rinsed 1 x time with DPBS minus Mg2+ 
and Ca2+ and re-pelleted.   Washed pellets were re-suspended in 500 µl Fix/Perm buffer 
(fixation/permeabilization solution, BD Biosciences), transferred to 5 ml round bottom 
flow cytometry tubes (BD Biosciences), and incubated for 40 min on ice.  Cells were 
then pelleted at 300 x g for 5 min and supernatant was aspirated.  Cells were washed 2 
x times with Perm/Wash buffer (BD Bioscience) and pelleted by centrifugation at 300 x 
g for 5 min.  Cells were blocked by adding 100 µl blocking buffer (BD Bioscience) to 
each tube and incubating on ice with gentle rocking for 30 min. Primary antibodies 
recognizing NKX2.5 (Abcam, ab91196) and MYH6 (Abcam, ab50967) at a 1:100 
dilution were added directly to the cell suspensions in each tube and incubated for two 
hrs on ice with gentle rocking.  To wash out primary antibodies, 3 ml of perm/wash 
buffer was added to each tube and then centrifuged at 300 x g for 5 min. Supernatant 
was aspirated and cells were washed with 2 ml/tube fresh Perm/Wash solution and 
centrifuged at 300 x g for 5 min.  For secondary antibody incubation, cell pellets were 
suspended in 100 µl blocking buffer with secondary antibodies at 1:400 dilutions.  Cells 
were incubated with rocking for 30 min on ice and then washed twice with perm/wash 
buffer.  Cells were then suspended in Flow Assay Buffer (BD Biosciences) and the 
percentage of NKX2.5+ and MYH6+ cells was determined using a FACS Aria flow 
cytometer and analyzed using FACS Diva (BD Bioscience) or FlowJo (FlowJo, LLC) 
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software in the Vanderbilt University Shared Flow Cytometry Resource Laboratory.  The 
total number of cardiomyocytes per well was calculated by multiplying the total cell 
number per well (as described above) by the percentage of NKX2.5+ or MYH6+ cells as 
determined by flow cytometry. 
 
Results 
 
hiPSC cardiac differentiation protocol for GREM2 treatment  
The results described in chapter 4 suggest inhibition of BMP signaling is 
necessary for cardiomyocyte differentiation of human iPS cells.  To test whether 
GREM2 can further enhance human cardiomyocyte differentiation, I added GREM2 
protein to differentiating iPS cells from day 3 onwards, when cardiogenic mesoderm 
appears and endogenous GREM2 expression begins to rise.  The “Matrix Sandwich” 
protocol (SP) served as a positive control, whereas a modified, truncated, “Matrix 
Sandwich” differentiation protocol (MP) without any factor addition after mesoderm 
induction at day 3 served as the baseline or negative control (Fig. 16).   
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GREM2 treatment accelerates the appearance of cardiomyocytes in cultured 
hiPSCs 
Visual comparison of culture revealed that GREM2 protein addition accelerated 
the appearance of contracting cells, indicating the presence of cardiomyocytes at day 7, 
which is 1 day earlier than the “Matrix Sandwich” method and 3 days earlier than the 
negative control (Fig. 17A).  In addition, GREM2 also increased the overall areas of 
contracting cells, suggesting further expansion of the cardiac lineage (Fig. 17B).  
 
 
 
 
Figure 16: Cardiac differentiation protocols for testing the effects of Grem2 
treatment on differentiating human pluripotent stem cells. Schematic diagram 
showing treatment schedule and conditions of the three differentiation protocols using DF 
19-9-11 iPS cells.  D -4 through D14 represent differentiation day minus 4 through day 14 
respectively.  Addition of growth factors and treatment duration are indicated below the 
time line. 
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GREM2 treatment causes robust induction of cardiac genes 
In agreement with the visual observations, analysis of RNA samples prepared at 
day 10 and 14 of differentiation showed that addition of GREM2 leads to a further 
increase in cardiac-specific gene expression levels compared to the “Matrix Sandwich” 
method (Fig. 18).  NKX2.5, MYH6 and TNNT2 were chosen as prototypical markers of 
cardiac cells. NKX2.5 is a transcription factor whose expression marks both committed 
cardiac progenitor cells and differentiated cardiomyocytes. MYH6 and TNNT2 code for 
cardiac contractile proteins and mark more mature, functional cardiomyocytes. These 
were chosen to gauge increases in the functional genes MYH6 and TNNT2 in samples 
B A 
Figure 17: Grem2 accelerates the appearance of spontaneously contracting cells 
and increases % of well with contracting cells. (A) Differentiating iPS cells treated with 
GREM2 (GREM2 D3-10) start contracting earlier than the “Matrix Sandwich” Protocol 
(SP) or the modified protocol (MP).  (B) Percentage of contracting areas in each well was 
measured on differentiation day 14 (D14) for each condition.  GREM2 treated wells had 
the highest percentage of contracting areas among the conditions tested, suggesting that 
GREM2 treatment is able to increase cardiac potential in differentiating iPS cells.  N = 9 
replicates per condition.  Student’s t test was used to compare conditions as indicated.  
***P < 0.001. 
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treated with GREM2. Gene expression response to GREM2 treatment was quite robust, 
with increases as high as 1600-fold compared to baseline and 25-fold versus the 
optimized Matrix Sandwich method in the case of NKX2.5. Interestingly, response to 
GREM2 treatment among the genes tested was not uniform, with NKX2.5 and MYH6 
being more sensitive to GREM2 treatment than TNNT2. This suggests that GREM2  
increases the number of cardiomyocytes but also the expression levels of genes such 
as NKX2.5 and MYH6 at various fold. 
 
 
 
 
 
 
 
 
 
 
GREM2 increases total amount of cardiomyocytes in culture 
To quantify the long-term effects of GREM2 on cardiomyocyte yields, I performed 
flow cytometry analysis at differentiation day 30 using antibodies recognizing the 
cardiac-specific myosin heavy chain MYH6.  I also used antibodies recognizing NKX2.5, 
Figure 18: Grem2 treatment increases the expression of cardiac genes. RT-qPCR 
analysis of cardiac genes shows that GREM2 treatment increases expression of the early cardiac 
gene NKX2.5 and the late cardiac genes MYH6 and TNNT2.  N = 3 replicates per condition.  
Student’s t test was used to compare conditions as indicated.  *P < 0.05; **P < 0.01. 
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the expression of which is maintained in mature CMs, thus providing an independent 
marker to quantify cardiac cells.   The data showed that GREM2 treatment gives rise to 
increased numbers of cardiomyocytes as compared to the “Matrix Sandwich” method 
(Fig. 19).  Specifically, GREM2 treatment increased the percentage of MYH6+ cells from 
~83% in the optimal Sandwich Protocol (SP) to ~93% and approximately doubled the 
total number of cells, thus increasing the total number of CMs/well as shown in Fig. 19.  
Similarly, the percentage of NKX2.5+ cells increased from ~70% to ~88%.  
Two populations of high and low NKX2.5+ expressing cells were observed in the 
flow cytometry experiments. Both of these populations were increased in GREM2 
treated samples compared to the standard protocol. However, when total 
cardiomyocytes were calculated it was the NKX2.5 high population that had the greatest 
proportional increase (5-6 fold vs 2 fold for the NKX2.5 low population). Although the 
significance of this observation is currently unknown, these results suggest that GREM2 
treatment affects both the quantity and quality of human iPSC-derived cardiomyocytes. 
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GREM2-BMP binding is required for cardiogenic effect of GREM2 
GREM2 is known to interfere with BMP signaling by binding to BMP ligands 
directly (Nolan et al., 2013, 2016). I hypothesized that BMP binding may be important 
for the cardiogenic effect of GREM2. To test this hypothesis I took advantage of a series 
of engineered GREM2 mutants that were developed in the lab of our collaborator Dr. 
Figure 19: Grem2 treatment increases the total number of cardiac cells in culture. 
Flow cytometry of iPS cell-derived cardiomyocytes at differentiation day 30 using 
antibodies recognizing NKX2.5 and MYH6.  GREM2 treatment increases the total number 
of cardiomyocytes compared to the “Matrix Sandwich” (SP) protocol.    Cardiomyocytes 
were observed as both high and low NKX2.5+ populations.  Cardiomyocytes with high 
NKX2.5 expression are particularly enriched by GREM2.  Quantification of the flow 
cytometry data is shown to the right.  N = 8 replicates.  Student’s t test.  ***P < 0.001. 
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Tom Thompson at the University of Cincinnati (Nolan et al., 2013). Each of the mutants 
contains an alanine substitution in the BMP ligand binding region that causes retention 
(F122A) or loss (F117A) of BMP binding activity as measured by surface plasmon 
resonance assays and cell based BMP-Luciferase reporter assays (Nolan et al., 2013). I 
then treated differentiating hiPS cells with these mutants and wild type GREM2 starting 
at day 4 of differentiation. qPCR analysis of cardiac genes showed that cells treated 
with the non-binding mutant did not show an induction of cardiac genes compared to 
control. Samples treated with the BMP binding mutant F122 showed an induction of 
cardiac genes comparable or greater than that observed with wild type GREM2 
treatment. These data show that BMP binding is required for GREM2 induced 
cardiogenic differentiation (Fig. 20).  
 
 
Figure 20: Treatment with Grem2 mutants reveals BMP binding is required for Grem2 
cardiogenic effect. RT-qPCR analysis of cardiac genes in differentiated iPC cells at 
differentiation day D10.  Cells were treated with 100 ng/ml of wild-type GREM2 (WT), a non-
BMP binding GREM2 mutant (F117A), and a strongly-binding mutant (F122A) during 
differentiation days 5-10.  Both the WT and the F122A mutant induce cardiac genes.  The 
F117A mutant was similar to non-treated controls (MP).  N = 3 replicates per condition.  
Student’s t test, **P < 0.01.  NS: not significant. 
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Cardiogenic effect of GREM2 is not cell line dependent 
As shown above, GREM2 treatment was sufficient to induce cardiogenesis in 
differentiating DF 19-9-11 hiPS cells. Due to interline variation among different 
pluripotent stem cell lines it is possible that the GREM2 effect is specific to the DF19-9-
11 cell line and not a universal property of GREM2 itself. To determine whether this 
effect was cell line independent I tested the effect of GREM2 treatment using a 
separate, independently derived, and well-characterized stem cell line, iMR90 C-4. The 
positive effect of GREM2 was also evident using the independent iMR90 C-4 hiPS cell 
line, indicating that the pro-cardiogenic properties of GREM2 are not limited to a single 
pluripotent stem cell line (Fig. 21).   
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Figure 21: GREM2 induces differentiation in an independent human iPS cell line.  (A) 
GREM2 treatment of the human iPS cell line (iM90 C4) during differentiation days 5-10 
accelerated the appearance of contacting cells in a similar fashion to DF 19-9-11 iPS cells 
described in Fig. 4.   GREM2-treated cultures presented contracting cells a day earlier than 
the “Matrix Sandwich” protocol (SP) or the modified baseline protocol (MP).  (B) RT-qPCR 
analysis of cardiac genes shows that GREM2 treatment increases expression of the cardiac 
genes MYH6 and TNNT2.  N=3 replicates per condition.  One-way ANOVA with Tukey’s 
HSD test.  **P <0.01; ***P < 0.001. 
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Taken together, these data demonstrate that GREM2 protein addition during 
cardiac differentiation accelerates and enhances the cardiogenic potential of 
differentiating human iPS cells.  
 
Summary 
 
 In this chapter I showed that using a modified version of the matrix sandwich 
protocol provided a suitable control condition wherein mesodermal cells were produced 
and to which GREM2 could be added in order to test the effects of GREM2 on cardiac 
differentiation. My results show that adding GREM2 to this baseline differentiation 
protocol was able to accelerate the appearance of cardiomyocytes and increase the 
total numbers and percentage of cardiomyocytes in culture when compared with the 
previously reported and optimized matrix sandwich protocol (Zhang et al., 2012). 
GREM2 treatment was also able to strongly induce cardiac specific genes at early and 
late time points in differentiating human stem cells. GREM2 mutants that were unable to 
bind BMP ligands were also unable to robustly induce cardiogenesis while mutants that 
retained their BMP ligand binding were able to induce cardiac differentiation. These 
effects were observed in both the DF 19-9-11 human pluripotent stem cell line and the 
IMR90-C4 hiPS cell line, suggesting that GREM2 plays a fundamental cardiogenic role 
in human cardiomyocyte differentiation. Taken together all of these data show that 
GREM2 is a cardiogenic molecule and that its cardiogenic properties require binding to 
BMP ligands.  
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 GREM2 treatment was sufficient to accelerate the appearance of contracting 
cells, increase the amounts of cardiac myocytes, and induce the expression of cardiac 
genes when compared with controls. This acceleration and increase in cardiogenesis is 
similar to that observed in mouse ES cells as discussed in chapter 3. Interestingly, no 
atrial cardiomyocyte subtype bias was observed in GREM2 treated hiPSC-derived 
cardiomyocytes. This is in contrast to the effects observed in mouse ES cells, which 
were selectively biased towards cardiomyocytes with functional properties characteristic 
of atrial cardiomyocytes. This difference may be due to differences in the role played by 
GREM2 among species, or could be due to the timing of addition of GREM2 or of the 
time points at which the cells were collected for observation. The effects of GREM2 on 
hiPSCs also share some similarity to that observed in the gain of function studies in 
zebrafish embryos as discussed in chapter 3. Injection of GREM2 was able to increase 
the amount of cardiac tissue produced in embryos and caused formation of 
cardiomyocytes in ectopic areas. These studies also showed a preferential bias of 
GREM2 towards producing atrial cardiomyocytes and tissues. This difference may 
indicate that GREM2 function in subtype selection is conserved in zebrafish and mouse 
but diverges in humans, or it could be that in order to observe a GREM2 effect on 
cardiomyocyte subtypes in human iPSCs it will be necessary to try a greater range of 
treatment time points to find the proper temporal context. 
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Chapter 7 
 
BMP Signaling Inhibition Promotes Proliferation of Cardiac Progenitor Cells 
 
Introduction 
 
During human pluripotent stem cell cardiac differentiation, cardiac progenitor 
cells form from mesodermal cells starting around day 3 or 4.  At this stage, expression 
of the mesodermal marker T BRY sharply decreases while expression of cardiovascular 
progenitor markers such as KDR and NK2.5 starts to rise. During this period of cardiac 
progenitor cell specification, cardiac progenitor cell populations also undergo expansion, 
presumably recapitulating the expansion of cardiac progenitors observed in vivo to 
satisfy the cell quantity requirements of a functional myocardium (Kuhn and Wu, 2010).  
Cardiac progenitor populations expand as the result of either specification of non-
cardiac progenitor cells to become cardiac progenitor cells, or by direct proliferation of 
already specified cardiac progenitor cells (Birket et al., 2015; Kuhn and Wu, 2010). 
Factors that affect either of these processes can be used to affect total numbers of 
cardiac progenitor cells in culture (Palpant et al., 2017).  
As already discussed, BMP signaling plays an important role in pluripotent stem 
cell differentiation. The expression data in chapter 4 show that genes for BMP 
molecules are being actively transcribed during the cardiac progenitor cell stage in the 
human pluripotent stem cell lines and differentiation protocols tested. In chapter 5, I 
showed that BMP inhibition by GREM2 was required for cardiac differentiation. I found 
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that GREM2 treatment during cardiac differentiation was able to increase the total 
numbers of cardiac cells and that this BMP ligand binding was required for this effect. 
So far however, it is unknown whether GREM2 and BMP inhibition are affecting cardiac 
progenitor cell specification, proliferation, and/or the transition of progenitor cells to 
cardiac myocytes.  
Here, pluripotent stem cells and the BMP inhibitors GREM2, NOGGIN, and DAN 
were used to distinguish among these possibilities. 
 
Materials and Methods 
 
Human pluripotent stem cell culture 
Human induced pluripotent stem cell lines iMR90 and DF 19-9-11 from WiCell were 
cultured under feeder free conditions in mTeSR1 or Essential 8 (E8) media (Stem Cell 
Technologies) as described in chapter 4.  
 
iPS cell differentiation 
Human iPS cells were differentiated using the “Matrix Sandwich” method as already 
described in chapter 4. As in chapter 6 at day 5, GREM2-treated wells received basal 
differentiation medium with 150 ng/ml of GREM2.  Media in all wells was replaced daily.  
Additionally, cells were treated in a similar fashion with 50 ng/ml NOGGIN or 1.5 µg/ml 
DAN, based on their specific activities (R&D Systems).    
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Immunofluorescence 
Cells were seeded onto Matrigel-coated (8.7 µg/cm2) 12-well plastic culture plates 
(Thermo Fisher Scientific) at a density of 500,000 cells per well and differentiated as 
described above for the “Matrix Sandwich” method.  Cells were fixed at the desired time 
points (differentiation days 4, 5, 6 and 10) by rinsing with 500 µl DPBS and incubating in 
4 % PFA in PBS at 4oC for 5 mins. The PFA solution was then aspirated and cells were 
rinsed with 1X PBS 5 times.  Fixed cells were permeabilized by incubating with 400 µl 
permeabilization buffer (0.2 % Triton X-100 in 1X PBS) in each well at room 
temperature for 1 hr.  Nonspecific binding was then blocked using 400 µl/well of 
blocking solution (5 % non-fat dry milk in permeabilization buffer) for 2 hrs at room 
temperature with gentle rocking.  For all subsequent steps, a minimum of 350 µl of 
solution was added to each well.  Cells were then washed 3 x 5 min with 400 µl/well of 
1X PBS at room temperature. After washing, cells were incubated with primary 
antibodies in incubation buffer (0.1 % Triton X-100, 1 % BSA in 1X PBS) overnight at 
4°C with gentle rocking.  Next, cells were washed 3 x 3 min each, with PBST (0.2 % 
Tween-20 in 1X PBS) followed by 3 x 3 min each with 1X PBS.  Cells were then 
incubated with secondary antibodies diluted in incubation buffer for 1 hr at room 
temperature in the dark.  Finally, cells were then washed 2 times, 3 min each, with 1X 
PBS and stored in 400 µL 1X PBS for imaging.  
 
Imaging was done using a Nikon C2 Confocal, Leica DM IRB Inverted Microscope or a 
Zeiss Laser Scanning Microscope (LSM 880).  Image analysis and volume rendering 
were done using NIS Elements, Zen, ImageJ/FIJI, and Imaris software suites.  Primary 
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antibodies recognizing phospho-HISTONE H3 (Santa Cruz Biotechnology, Cat# sc-
8656-R, 1:500), NKX2.5 (Santa Cruz Biotechnology, sc-8697, 1:50), GREM2 
(ProteinTech, 13892-1-AP, 1:100), and α-ACTININ (Sigma, A7811, 1:500) were applied.  
I have also tested anti-GREM2 rabbit polyclonal antibodies from GeneTex 
(GTX108414), Abcam (ab102563) and R&D Systems (AF2069) at 1:100 dilution.  The 
fluorescent dye 4’,6-diamidino-2-phenylindole (DAPI; Invitrogen) was added during the 
final 15 mins of secondary incubation at a 1:10,000 dilution to stain nuclei. 
 
Western blotting 
 
Protein samples from differentiated hiPS cells (DF 19-9-11, WiCell) were isolated using 
the RIPA buffer, including the Protease Inhibitor Cocktail and Phosphatase Inhibitor 
Cocktail 2 and 3 (Sigma) diluted at 1:100.  Cell lysates were shaken at 4oC for 30 min 
and centrifuged at 12,000 rpm at 4oC for 15 min.  Protein concentration in supernatants 
was measured using the Pierce BCA protein assay (Thermo Fisher Scientific).  15 µg of 
protein (adjusted to 7.5 µl with distilled water) was then mixed with 7.5 µl of 2X Laemmli 
Sample Buffer (Bio-Rad) containing β-Mercaptoethanol (Sigma).  Proteins were 
denatured at 95oC for 5 min, then placed on ice for another 5 min.  Electrophoresis was 
run using sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) with 1X MOPS SDS 
running buffer (Life Technologies).  Size fractioned proteins were transferred to 
nitrocellulose membranes (Bio-Rad) using the semidry system.  Membranes were 
blocked with 5% dry milk or 5% BSA (Sigma) in Tris-buffered saline (Corning) 
containing 1 % Tween-20 (Sigma) (1X TBST) for 1 hr at room temperature or 4oC, 
respectively.  Next, membranes were incubated overnight with antibodies recognizing 
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NKX2.5 (Santa Cruz Biotechnology, sc-8697) diluted at 1:500 and β-ACTIN (Sigma 
Aldrich, A1978) diluted at 1:5,000 in 5% BSA in 1X TBST.  Next day, membranes were 
washed 3 times, 5 min each with TBST and incubated for 2 hrs at room temperature 
with peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch) diluted 
1:5,000 in 5% dry milk-TBST.  Three 5 min washes were performed to wash away 
unbound secondary antibodies.  Signals were detected using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific) and images were taken with 
ChemiDoc Touch System (Bio-Rad).  Protein band intensities were quantified using 
ImageJ. 
 
Results 
 
GREM2 Promotes Proliferation of Cardiac Progenitor Cells  
Western blotting analysis of NKX2.5 protein, showed that GREM2 does not affect 
the initial induction of early cardiac genes (Fig. 22).   
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Instead, the GREM2 expression during the initial appearance of cardiac 
progenitor cells (CPCs) and its stimulatory effect on cardiac differentiation raised the 
possibility that GREM2 promotes proliferation of CPCs.  To directly test this possibility, I 
stained GREM2-treated differentiating iPS cells with antibodies recognizing the 
phosphorylated form of HISTONE H3 (pHH3) that is specifically phosphorylated during 
the mitosis and meiosis phases of cell division, thereby marking proliferating cells.  The 
“Matrix Sandwich” (SP) and baseline (MP) protocols as outlined above in Fig. 16 served 
as positive and negative controls, respectively. 
 
The results demonstrate that addition of GREM2 protein at day 3 leads to a 5-6 
fold increase in pHH3+ cells at day 4 (Fig. 23 and Fig. 24).  At this stage, pHH3 
colocalizes with cell colonies expressing the early cardiovascular progenitor-specific 
membrane receptor KDR (or VEGFR2) (Yang et al., 2008b).  Notably, KDR expression 
Figure 22: GREM2 does not affect specification of cardiac progenitor cells and early 
expression of cardiac marker NKX2.5.  Western blotting analysis at differentiation days 6 
and 8 of iPS cell differentiation with an anti-NKX2.5 antibody shows similar NKX2.5 protein 
levels at day 6 between GREM2-treated samples and baseline (MP) controls but increased 
NKX2.5 protein by GREM2 treatment at day 8.  β-ACTIN served as loading control. 
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diminishes in SP cultures compared to MP and even more in GREM2-treated cells, 
likely due to acceleration of cardiac differentiation and loss of vascular markers, which is 
consistent with the timing of appearance of contracting cells under the different 
protocols at later stages (Fig. 17).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: GREM2 promotes proliferation of cardiovascular progenitor 
cells.  Immuno-fluorescence staining of cardiac progenitor cells during iPS 
cell differentiation.  Cells were treated with GREM2 and compared to “Matrix 
Sandwich” (SP) and baseline negative controls (MP) as described in Fig. 11. 
Representative images of cell cultures stained at differentiation day 4 with 
the cardiovascular progenitor marker KDR (red) and the active proliferation 
marker pHH3 (green) show that GREM2 treatment increases the total 
number of proliferative cells.  Scale bars, 30 μm. DAPI staining (blue) marks 
cell nuclei. Abbreviations: pHH3: phospho-HISTONE H3 
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At day 5, pHH3 is specifically found in the nuclei of NKX2.5+ CPCs (Fig. 20).   
The immunofluorescence analysis results show that GREM2 promotes proliferation of 
CPCs.  Interestingly, the “Matrix Sandwich” protocol, which requires BMP4 addition at 
differentiation days 3-5, initially generates less proliferating CPCs than the other 
conditions (Fig. 23 - 25).  However, the “Matrix Sandwich” protocol eventually promotes 
cardiomyocyte differentiation after BMP4 removal at day 5, but not to the same extent 
as addition of GREM2.  
 
 
 
Figure 24: Grem2 increases the total number of proliferative cells in 
differentiating human iPS cells.  Left, Quantification of total numbers of 
pHH3 positive cells in immunostained iPS cells at differentiation day 5 shows 
a higher number in GREM2-treated wells. Right, Quantification of total 
numbers of pHH3/NKX2.5 double positive cells in immunostained iPS cells 
at differentiation day 5 shows that in GREM2-treated wells there are a higher 
number of double labeled cells, suggesting GREM2 treatment increases the 
amount of proliferating cardiac progenitor cells.  N = 9 replicates per 
condition.  One-Way ANOVA with Tukey’s HSD test.  *P <0.05; **P < 0.01.   
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BMP inhibition promotes proliferation of cardiac progenitor cells  
The results described in the previous sections show that GREM2 promotes 
proliferation of CPCs.  To test whether inhibition of BMP is sufficient to also stimulate 
cardiac differentiation, I compared the effects of GREM2 to two additional, distinct BMP 
antagonists, namely NOGGIN and DAN (Fig. 26).   
Figure 25: GREM2 promotes proliferation of cardiac progenitor cells.  
Staining at day 5 with the cardiac progenitor cell marker NKX2.5 (red) shows 
co-localization with pHH3 (green), indicating increased proliferation of 
cardiac progenitor cells in GREM2-treated cultures of differentiating iPS 
cells.  Representative double-positive cells are marked by arrows.  Scale 
bars, 100 μm.  DAPI staining (blue) marks cell nuclei.  Abbreviations: pHH3: 
phospho-HISTONE H3 
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To test whether the selected BMP antagonists could inhibit BMP signaling in 
differentiating hiPS cells RNA was collected from cells treated with each antagonist and 
analyzed for activation of the canonical BMP signaling target gene ID2. All three BMP 
antagonists led to suppression of the canonical BMP signaling target gene ID2, 
respectively, showing they function as expected (Fig. 27A).  Treatment with any of the 
three BMP antagonists led to a significant increase in overall cell numbers (Fig. 27B). 
 
Figure 26: Protocols for testing effects of BMP antagonists on cardiac differentiation.  
Schematic diagram showing treatment schedule and conditions of iPS cell differentiation 
using DF 19-9-11 human iPS cells.  D-4 through D10 represent differentiation day minus 4 
through day 10 respectively.  Addition of various BMP antagonists is indicated on the left. 
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Co-staining of differentiating iPS cells at day 6 with antibodies recognizing 
NKX2.5 and pHH3 showed that GREM2-treated cells had higher proliferation rates than 
baseline.  NOGGIN and DAN also increased CPC proliferation, compared to baseline 
(Fig. 28).  Of note, there were comparable numbers of NKX2.5+ cells at day 6 in control 
and BMP antagonist-treated differentiating iPS cells, further confirming that GREM2 and 
BMP signaling antagonists do not abort the specification of CPCs.  
 
A B 
Figure 27: BMP inhibition causes an increase in the total number of cells 
per well.  (A) RT-qPCR analysis of the canonical BMP signaling target gene 
ID2 at differentiation day 5.  All 3 BMP antagonists, GREM2 (G2), NOGGIN 
(NOG), and DAN suppress ID2 expression.  N = 3 replicates per condition.  *P 
<0.05; One-way ANOVA with Tukey’s HSD test.  (B) Total cell numbers were 
quantified using the live nuclear stain Nuc Blue at day 10 of differentiation.  All 
3 BMP antagonists increase the total numbers of cells per well.  N = 6 
replicates per condition. *P <0.05. One-way ANOVA with Tukey’s HSD test. 
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Figure 28: BMP inhibition promotes proliferation of cardiac progenitor cells. 
Immunostaining of cardiac progenitor cells at day 6 of iPS cell differentiation with the 
proliferation marker pHH3 (green) and the cardiac progenitor cell marker NKX2.5 (red).  
DAPI staining (blue) marks cell nuclei.   Cells were treated with the BMP inhibitors GREM2, 
NOGGIN and DAN as indicated in panel A.  All three BMP inhibitors induce proliferation of 
cardiac progenitor cells.  Scale bar, 100 μm.   
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BMP inhibition is not sufficient to induce cardiac differentiation 
To test whether BMP signaling inhibition is sufficient to promote cardiomyocyte 
differentiation, I isolated RNA samples at day 10 of differentiation from cells treated as 
shown in Fig. 26.  Quantitative PCR analysis showed that GREM2 led to induction of 
cardiac-specific gene markers characteristic of contracting CMs such as MYH6 and 
TNNT2, but NOGGIN and DAN had minimal or no effect (Fig. 29).  Therefore, although 
all three BMP antagonists enhanced proliferation of NKX2.5+ cells, induction of 
cardiomyocyte (CM) differentiation was a characteristic specific to GREM2.    
 
 
 
 
 
 
 
 
 
 
Figure 29: BMP inhibition is not sufficient to induce cardiac-specific genes. RT-
qPCR analysis of cardiac genes MYH6, NKX2.5, TNNT2 and MYL7 at day 10 of 
differentiation show an increase in cardiomyocyte gene induction at later time points 
in GREM2-treated iPS cells while a similar increase in gene induction was not 
observed for the other BMP antagonists.  N = 3 replicates per condition. ***P < 0.001. 
One-way ANOVA with Tukey’s HSD test. 
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Summary 
 
 In this chapter I have examined the effect of BMP inhibition on cardiac progenitor 
cell specification, proliferation, and differentiation to cardiomyocytes. The results show 
that treatment of differentiating human stem cells with GREM2 as cardiac progenitor 
cells are forming increases the total numbers of cells in culture by inducing proliferation 
of cardiac progenitor cells. GREM2 treatment did not affect specification of cardiac 
progenitor cells but instead acts on previously specified cardiac progenitors. Treatment 
of differentiating cells with other BMP antagonists showed that proliferation of cardiac 
progenitor cells was a common effect of various BMP antagonists, suggesting that 
cardiac progenitor cell expansion is not unique to GREM2.  
There are reports in the literature of using BMP inhibitors to increase the 
cardiogenic potential of pluripotent stem cells (Yuasa et al., 2005; Hao et al., 2008). 
These reports indicate an increase of differentiated, functional cardiomyocytes after 
treatment with inhibitors such as Noggin or the small molecule BMP inhibitor 
dorsomorphin (Yuasa et al., 2005; Hao et al., 2008). Expansion of cardiac progenitor 
cell populations could partially be responsible for an increase in cardiomyocytes as 
reported, however the subsequent cardiomyocyte differentiation of these cells reported 
by Yuasa and Hao contradicts what was observed in my hiPSC experiments. This is 
likely due to timing of treatment. In both experimental protocols by Yuasa and Hao the 
pluripotent stem cells were treated prior to the start of differentiation. Thus adding BMP 
inhibitors may have had a priming effect on pre-differentiated stem cells. These 
methods also used the embryoid body method, which may have provided the additional 
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cellular signaling clues required for proper differentiation of increased numbers of 
cardiac progenitor cells.   
 GREM2 was the only BMP inhibitor tested that was able to promote the 
differentiation of cardiac progenitor cells to cardiomyocytes. This unique property of 
GREM2 is likely due to its unique structural and binding properties when compared to 
DAN and Noggin (Nolan et al., 2016). GREM2 is able to form heterodimers with BMP 
ligands that then become new functional signaling units (Nolan et al., 2013; Nolan and 
Thompson, 2014b; Nolan et al., 2016). These new complexes may be able to affect 
BMP signaling by unique receptor binding paradigms not shared by Noggin and DAN. 
GREM1, a closely related protein to GREM2 is known to directly interact with additional 
receptors not traditionally considered part of canonical BMP signaling (Nolan and 
Thompson, 2014b). Reports in the literature indicate that GREM1 is able to promote 
angiogenesis via activation of the VEGF receptor VEGFR2 (Mitola et al., 2010). It was 
further reported that GREM1 could still bind and activate VEGFR2 even in complex with 
BMP ligands (Mitola et al., 2010). Due to the highly similar structures of GREM1 and 
GREM2 it is likely that GREM2 may also be able to signal through other pathways by 
yet unstudied direct receptor interactions. 
My data show that the transition from progenitor cell to cardiomyocyte was 
facilitated by GREM2 treatment but not that of other BMP inhibitors. This points to a 
unique role for GREM2 at the junction between progenitor cell proliferation and 
differentiation in human cardiogenesis. At this point, the mechanism behind this unique 
property of GREM2 remains unexplored. 
 
104 
 
Chapter 8 
 
GREM2 Specifically Induces Cardiomyocyte Differentiation Through JNK 
Signaling Activation 
 
Introduction 
 
 In chapter 7, I described data to show that GREM2 was able to induce 
proliferation of cardiac progenitor cells and that this was a property of BMP antagonists 
in general. I further showed that GREM2 was also able to induce differentiation of 
cardiac progenitors to cardiomyocytes, which was unique to GREM2 among the BMP 
antagonists tested. This suggests that GREM2 is able to act through a unique 
mechanism not shared by the other antagonists. 
 BMP signaling occurs via canonical, Smad mediated signaling activation or can 
involve non-canonical JNK-mediated signaling activation (Wang et al., 2014). Previous 
studies have shown that GREM2 is able to affect cardiac differentiation by selectively 
activating JNK signaling and that this property is unique to GREM2 (Tanwar et al., 
2014). It is possible that this selective activation of JNK signaling also plays a role in 
GREM2 mediated cardiac differentiation of human pluripotent stem cells. To address 
this possibility, Western blotting and the use of JNK signaling inhibitors were employed 
to determine if JNK activation by GREM2 is required for cardiac differentiation of human 
pluripotent stem cells. 
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Materials and Methods 
 
Human pluripotent stem cell culture 
Human induced pluripotent stem cell lines iMR90 and DF 19-9-11 from WiCell were 
cultured under feeder free conditions in mTeSR1 or Essential 8 (E8) media (Stem Cell 
Technologies) as already described in chapter 4.  
 
iPS cell differentiation 
Human iPS cells were differentiated using either the “Matrix Sandwich” method, the 
GiWi method, or the BMP/ACTIVIN A method as described in chapters 5 and 6. 
Differentiating stem cells were treated starting at days 3 or 5 with 5µM JNKi 6o (Tocris 
Biosciences) in a similar fashion as described for GREM2.    
   
Western blotting 
 
Protein samples from differentiated hiPS cells (DF 19-9-11, WiCell) were isolated using 
the RIPA buffer, including the Protease Inhibitor Cocktail and Phosphatase Inhibitor 
Cocktail 2 and 3 (Sigma) diluted at 1:100.  Cell lysates were shaken at 4oC for 30 min 
and centrifuged at 12,000 rpm at 4oC for 15 min.  Protein concentration in supernatants 
was measured using the Pierce BCA protein assay (Thermo Fisher Scientific).  15 µg of 
protein (adjusted to 7.5 µl with distilled water) was then mixed with 7.5 µl of 2X Laemmli 
Sample Buffer (Bio-Rad) containing β-Mercaptoethanol (Sigma).  Proteins were 
denatured at 95oC for 5 min, then placed on ice for another 5 min.  Electrophoresis was 
run using sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) with 1X MOPS SDS 
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running buffer (Life Technologies).  Size fractioned proteins were transferred to 
nitrocellulose membranes (Bio-Rad) using the semidry system.  Membranes were 
blocked with 5% dry milk or 5% BSA (Sigma) in Tris-buffered saline (Corning) 
containing 1 % Tween-20 (Sigma) (1X TBST) for 1 hr at room temperature or 4oC, 
respectively.  Next, membranes were incubated overnight with antibodies recognizing 
phosphorylated SMAD 1/5/9 or total SMAD1 and phosphorylated or total JNK 1&2 (Cell 
Signaling) diluted at 1:1,000 in 5% BSA in 1X TBST.  Next day, membranes were 
washed 3 times, 5 min each with TBST and incubated for 2 hrs at room temperature 
with peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch) diluted 
1:5,000 in 5% dry milk-TBST.  Three 5 min washes were performed to wash away 
unbound secondary antibodies.  Signals were detected using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific) and images were taken with 
ChemiDoc Touch System (Bio-Rad).  Protein band intensities were quantified using 
ImageJ.  
 
Results 
 
GREM2 activates JNK signaling in differentiating human induced pluripotent stem 
cells 
We have previously shown that GREM2 inhibited canonical BMP, i.e., 
SMAD1/5/8-mediated signaling shortly after treatment of differentiating mouse ES cells, 
followed by JNK signaling activation at later stages.  Moreover, we found that this dual 
effect on canonical BMP signaling inhibition and subsequent non-canonical JNK 
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signaling activation is a unique property of GREM2 compared to Noggin, a typical BMP 
antagonist that has been well-characterized (Groppe et al., 2002; Zhu et al., 2006; 
Tanwar et al., 2014).  To test whether JNK activation drives cardiogenic differentiation 
of human iPS cells by GREM2, I prepared protein samples at differentiation days 4, 5, 
6, 7 and 8 of GREM2 and NOGGIN treated cells.  The “Matrix Sandwich” and baseline 
protocols served as positive and negative controls, respectively (as described in Fig. 
16).  Western blotting analysis using antibodies recognizing activated phospho-
SMAD1/5/8 showed that both GREM2 and NOGGIN effectively blocked SMAD 
phosphorylation 24 hrs after treatment (Fig. 29).  Phospho-SMAD1/5/8 levels became 
undetectable in all samples at subsequent time points (not shown).   There was no JNK 
phosphorylation at days 4-7 (not shown).   In contrast, Western blotting showed that 
phospho-JNK1/2 protein was specifically activated by GREM2 at day 8, but not 
NOGGIN (Fig. 29).  Of note, there was no JNK activation by the Matrix Sandwich 
method at this stage, suggesting either alternative pro-cardiogenic mechanisms are 
induced by this method, or GREM2 accelerates JNK signaling activation. 
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JNK signaling activation is required for GREM2 induced human cardiomyocyte 
differentiation 
To test whether JNK activation by GREM2 drives human cardiomyocyte 
differentiation, I exposed GREM2-treated differentiating iPS cells to the JNK signaling-
specific chemical inhibitor TCS JNK 6o  (JNKi 6o, (Kauskot et al., 2007; 
Szczepankiewicz et al., 2006)) or vehicle control.  Visual observations and RNA 
analysis by qPCR showed that JNK signaling inhibition abolished the stimulatory effect 
of GREM2 on the cardiac lineage expansion (Fig. 31).  Of note, JNK inhibition was 
effective when applied during differentiation of CPCs after day 5.   
 
 
 
Figure 30: GREM2 treatment induces JNK signaling in differentiating 
hiPS cells.   DF 19-9-11 iPS cells were differentiated according to the 
Matrix Sandwich method (SP), baseline control method (MP), or treated 
with GREM2 or NOGGIN (NOG) from day 3 (as described in Fig. 11 and 
21).  Protein lysates for Western blotting analysis were collected at 
indicated differentiation time points and analyzed using antibodies 
recognizing the phosphorylated forms of SMAD1/5/8 [expected Molecular 
Weight (MW) 60 kD] and JNK1/2 isoforms (46 and 54 kD, respectively) 
and total SMAD1 and JNK1/2 proteins.  Both NOGGIN and GREM2 
effectively inhibit SMAD phosphorylation at day 4.  In contrast, only 
GREM2 treatment leads to strong upregulation of JNK phosphorylation at 
day 6.  Graphs on the right represent quantification of phosphorylated 
SMAD and JNK forms relative to the corresponding total protein levels.  
One-way ANOVA with Tukey’s HSD test.  *P < 0.05. **P < 0.01.ANOVA 
with Tukey’s HSD test. 
110 
 
 
Figure 31: JNK signaling is required for GREM2-induced cardiac differentiation.   
(B) Differentiating DF 19-9-11 iPS cells were treated with GREM2 alone and either with 
GREM2 and the selective small molecule JNK inhibitor TCS JNK 6o (JNKi 6o) or 
vehicle as control (DMSO). Addition of JNKi 6o to GREM2-treated wells during the 
entire cardiac differentiation phase (Days 3-14) or just the late cardiac differentiation 
phase (Days 5-14) reduced the total percentage of contracting cells in each well.  N = 3 
replicates per condition.  One-way ANOVA with Tukey’s HSD test.  *P < 0.05; ** P < 
0.01.  (C) RT-qPCR analysis of cardiac genes NKX2.5 and MYH6 at day 14 of 
differentiation shows a reduction of cardiac gene expression in cells co-treated with 
GREM2 and JNKi 6o.  N = 3 replicates per condition.  Unpaired t-test.  *P < 0.05, **P < 
0.01. 
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Summary 
 
The results described in this chapter show that GREM2 treatment of 
differentiating human pluripotent stem cells is able to induce JNK signaling when 
compared to controls. Furthermore, this induction is unique to GREM2 and not shared 
by other BMP antagonists such as NOGGIN. When cells were concurrently treated with 
GREM2 and a JNK signaling inhibitor during the later stages of differentiation (days 5-7) 
as progenitor cells are transitioning to cardiomyocytes, the cardiogenic effect of GREM2 
was severely diminished.  
These data provide additional insight into how GREM2 is able to increase 
proliferation of cardiac progenitors in common with other BMP antagonists but has the 
additional property of inducing cardiac differentiation as well. In all cases tested thus far, 
the ability of GREM2 to modulate both BMP and JNK signaling has proven to be critical 
for its effects on cardiac differentiation in general (Tanwar et al., 2014). 
It is interesting that in this case the effective window for addition of JNK inhibitor 
to abolish the cardiogenic effects of GREM2 was at the latter stages of differentiation as 
cardiac progenitor cells are transitioning to cardiomyocytes. This specificity is 
remarkable in that it presents a new signaling regulation paradigm, wherein a single 
molecule (in this case GREM2) is able to act as a molecular switch that transitions from 
BMP inhibition to JNK activation at precisely the right time to facilitate cardiomyocyte 
differentiation. This possibility is supported by reports in the literature that JNK signaling 
plays a key role in lineage specific differentiation of pluripotent stem cells (Xu and 
Davis, 2010) 
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Chapter 9 
 
Conclusions, Discussion, Significance, and Future Directions 
 
Conclusions 
My thesis work has demonstrated that expression of the secreted BMP 
antagonist GREM2 is induced in pluripotent stem cell-derived human cardiac progenitor 
cells shortly after the specification of cardiac mesoderm.  GREM2 expression is 
maintained in cardiac progenitor cells throughout their differentiation and persists in 
differentiated cardiomyocytes.  BMP signaling antagonism is required for cardiac 
lineage development, since BMP ligand decoys that bind antagonists, but do not 
activate BMP receptors, abort cardiomyocyte differentiation.   My results further show 
that GREM2 increases cardiac gene expression and cardiomyocyte differentiation, a 
process that depends on JNK signaling activation.  Interestingly, although BMP 
antagonists such as NOGGIN and DAN equally stimulate cardiac progenitor cell 
proliferation, only GREM2 efficiently promotes differentiation to cardiomyocytes.  All 
together these data show that GREM2 coordinates cardiogenic output in a 2-step 
mechanism, initially inhibiting canonical BMP signaling to promote CPC proliferation 
followed by induction of differentiation through JNK signaling activation (Fig. 32). 
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Discussion 
BMP ligands play crucial roles at various stages of cardiac development (van 
Wijk et al., 2007), starting from the initial cardiogenic specification of mesoderm  
(Kruithof et al., 2006), to subsequent cardiac tube assembly, asymmetric looping and 
jogging (Breckenridge et al., 2001), ventricular identity (Marques and Yelon, 2009), 
outflow track and cushion formation (Ma et al., 2005) and cardiomyocyte differentiation  
(Pater et al., 2012).  Although canonical BMP signaling induces NKX2.5 gene in the 
cardiac crescent to generate cardiac progenitor cells, BMP signaling needs to be 
suppressed to allow proliferation and expansion of cardiac progenitor cells.  
Interestingly, during mouse secondary heart field development, Nkx2.5 suppresses 
Figure 32: GREM2 regulates cardiac proliferation and differentiation in 
human induced pluripotent stem cells.   Schematic diagram of the proposed 
role of GREM2 in regulating cell signaling during human cardiac differentiation. 
As cells progress from cardiac progenitors towards more committed cardiac 
cells GREM2 blocks BMP signaling to induce proliferation of cardiac progenitor 
cells and activates JNK signaling to promote differentiation. 
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BMP signaling by blocking pSmad1, forming a negative regulatory loop that promotes 
proliferation of cardiac progenitor cells (Kempf et al., 2011). This work shows that this 
mechanism likely applies to human cardiac progenitor cells as BMP signaling inhibition 
by either NOGGIN, GREM2, or DAN proteins promotes proliferation of cardiac 
progenitor cells.   
On the other hand, elegant gain and loss-of function studies in mouse embryos 
have shown that persistent BMP signaling inhibition prevents differentiation of cardiac 
progenitor cells (Prall et al., 2007).   These data confirm that NOGGIN and DAN prevent 
expression of genes specific to differentiated cardiomyocytes, including sarcomere 
proteins such as MYH6 and TROPONIN T2.  In contrast, GREM2, after the initial 
stimulation of cardiac progenitor cell proliferation, leads to robust induction of cardiac 
differentiation.  We have previously shown that GREM2 has the unique property among 
BMP antagonists, after its prescribed canonical BMP signaling inhibition, to 
subsequently induce JNK signaling activation that is required for cardiac differentiation  
(Tanwar et al., 2014).  These results indicate that this GREM2 property is responsible 
for promotion of human cardiac cell differentiation as well, since JNK signaling inhibition 
aborts the pro-cardiogenic effect of GREM2.  These findings are consistent with 
previous reports that have implicated JNK signaling in cardiogenic differentiation of 
pluripotent stem cells (Kempf et al., 2011; Ou et al., 2016). 
Recent crystallographic evidence revealed that GREM2 folds into a unique tertiary 
shape that has not been described before.  Specifically, GREM2 dimerizes in a head-to-
tail manner, unlike the head-to-head pairing of NOGGIN (Groppe et al., 2002; Nolan et 
al., 2013, 2016).  This head-to-tail arrangement gives rise to large, constrained and 
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arching hydrophobic surfaces on the 3-D structure, which precludes GREM2 from 
wrapping around BMP dimers as NOGGIN does (Groppe et al., 2002; Nolan et al., 2013, 
2016).  In this work I tested whether this unique structural arrangement is also critical for 
the function of GREM2 in regulating both proliferation and differentiation of cardiac 
progenitor cells.  Future biochemical analyses may further identify critical structural motifs 
that could be exploited to design molecules that mimic the biological effects of GREM2, 
such as the ability to selectively alter its BMP inhibitory and JNK activating properties.  
Recognizing these mechanisms may offer additional novel insights in the cardiac 
differentiation process.  Moreover, due to the wide interest in regulating BMP signaling in 
a number of human diseases, numerous BMP signaling inhibitors are being developed 
for clinical use (Ideno et al., 2009; Kriebitz et al., 2009).  Thus, these findings may facilitate 
future repurposing of these new pharmacological resources for coordinated growth and 
differentiation of stem cell populations. 
It was recently established that during embryonic development in zebrafish, 
GREM2 first appears in the pharyngeal mesoderm next to the forming heart tube (Müller 
et al., 2006, 2013).  Loss- and gain-of-function approaches demonstrated that GREM2 is 
necessary for proper cardiac tube jogging and looping, cardiac laterality and 
cardiomyocyte differentiation by suppression of Smad1/5/8 phosphorylation (Müller et al., 
2013).  Although, left/right asymmetry and complex morphogenetic processes cannot be 
replicated in cell culture, our data show that the critical role of GREM2 in cardiomyocyte 
differentiation has been conserved across species and applies to human pluripotent stem 
cells.   Moreover, it has been shown by this laboratory that GREM2 is critical for atrium 
formation in zebrafish and promotes differentiation of pluripotent mouse embryonic stem 
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(ES) cells to atrial-like cardiomyocytes (Tanwar et al., 2014).  I did not detect preferential 
induction of atrial- versus ventricular-specific genes in the examined early stages of 
GREM2-treated human iPS cells (data not shown).  Because human cardiomyocytes take 
longer to mature in culture than mouse cells (Mummery et al., 2002), it is likely that longer 
treatment periods might be required to test whether GREM2 can regulate chamber 
identity in iPS cell-derived cardiomyocytes. 
 In the adult mouse heart, it was recently discovered that GREM2 expression is 
highly induced in peri-infarct cardiomyocytes at the end of the inflammatory phase after 
myocardial infarction.  Using genetic gain- and loss-of-GREM2-function mouse models 
and chemical compounds that inhibit BMPs, it was discovered that GREM2 modulates 
the magnitude of the inflammatory response and keeps inflammation in check through 
suppression of canonical BMP signaling (Sanders et al., 2016).  GREM2 levels after 
myocardial infarction correlate with functional recovery, suggesting a new strategy to 
control inflammation of cardiac tissue after acute ischemic injury and improve cardiac 
function. It is intriguing that the BMP developmental pathway that initiates cardiac 
specification is also among the earliest induced after ischemic injury in the adult heart, 
but assumes a very different role.  It is also intriguing that GREM2 induction takes place 
in peri-infarct cardiomyocytes indicating reactivation of cardiomyocyte-specific 
expression of GREM2 takes place under pathological conditions.   However, unlike in 
developing cardiomyocytes, GREM2 does not induce cell proliferation in the adult heart.   
Understanding how this property is lost in adult cardiomyocytes might open the way to 
unlock cardiac regenerative mechanisms. 
 
117 
 
 
Significance 
 Human pluripotent stem cells hold great promise as a source of cardiac tissues 
for therapeutic use, as model systems for disease, and for gaining insights into the 
basic mechanisms of development (Bellin et al., 2012; Passier et al., 2016). To make 
good on this promise it is necessary to understand the mechanisms that drive cardiac 
differentiation in differentiating stem cells. Current studies and protocols have built on 
work in the field that has revealed how to quickly produce beating cells with properties 
of cardiomyocytes, including spontaneous contractility, the ability to metabolize lactate 
or pyruvate, and to a limited degree the specialized functions of cardiac subtypes, 
mostly of the ventricular subtype (Burridge et al., 2012; Mummery et al., 2012). These 
protocols have been generated at a rapid pace in a race to be first to generate the 
highest purity, greatest number of cardiomyocytes efficiently and quickly. Still lagging 
behind are studies that focus purely on the basic mechanisms that underlie cardiac 
differentiation in human pluripotent stem cells. 
 This work adds to our knowledge of the basic mechanisms that drive cardiac 
differentiation in human pluripotent stem cells. As has been reported for many growth 
factors and small molecules (Yuasa et al., 2005; Laflamme et al., 2007b; Hao et al., 
2008; Kattman et al., 2011; Rai et al., 2011; Lian et al., 2013), GREM2 is able to 
enhance the cardiogenic differentiation of human pluripotent stem cells. However, this 
work reveals a unique signaling paradigm at play within differentiating stem cells 
wherein GREM2 sits at the transition point between proliferation of cardiac progenitor 
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cells and differentiation towards cardiomyocytes. The importance of such a mechanism 
in biological systems is apparent. As stem cells make the progressive journey from 
pluripotency to specific somatic cells, they must transition from progenitor populations to 
increasingly more functional and specialized populations (Birket et al., 2015; Burridge et 
al., 2012). These transitions must occur at precise points on the temporal and spatial 
level. To achieve this regulation, growth factor expression and secretion is highly 
regulated so that growth factor gradients appear and are sequestered at the proper 
times and places (Bruneau, 2013). GREM2 is able to bind BMP ligands, increase 
cardiac progenitor cell proliferation, and induce differentiation of cardiac progenitor cells. 
It accomplishes this by affecting both canonical Smad mediated BMP signaling and 
non-canonical BMP signaling through the JNK pathway. This reveals a mechanism by 
which switching from canonical to non-canonical BMP signaling can achieve a regulated 
transition from proliferating progenitor cells towards differentiated somatic cells. 
 This work also gives biological context to recent advances in our understanding 
of the structure and biochemical properties of GREM2 and its unique GREM2:BMP 
complexes (Kattamuri et al., 2012a; Nolan et al., 2013, 2016). Our work reveals 
important information about the putative biological roles of these unique 
GREM2:BMP/receptor complexes. It is likely that the ability of GREM2 to affect 
proliferation and differentiation relies to some degree on its specific biochemical 
properties.   
 This work also has applications in human cardiac development. While not a 
complete replication of the developing embryo, lacking the complete physiological 
system with its host of tissues and complex, dynamic cellular signaling interactions, 
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differentiating human stem cells provide a relatively high fidelity model of human 
development (Passier et al., 2016). In that case, it is likely that the molecular switch role 
played by GREM2 in differentiating hu12 
man pluripotent stem cells is also important in human cardiac development. Indeed 
GREM2 mutants have been associated with cardiac disease in a clinical setting, and 
while the causal connection between GREM2 mutants and cardiac disease is still under 
investigation, it is possible that these GREM2 mutants fail to properly perform their 
intended function during development, leading to dysfunctional cardiac tissues (Müller 
et al., 2013).   
 
Future Directions 
This work has revealed a role for GREM2 in regulating human cardiac 
differentiation. While the context of GREM2 expression and localization was 
established, and gain of function studies using purified GREM2 protein revealed that 
GREM2 is sufficient to increase cardiogenesis in differentiating cardiomyocytes, more 
conclusive loss of function studies must be carried out to determine if GREM2 is 
specifically necessary for proper cardiac differentiation in human pluripotent stem cells. 
The work described here shows that sequestration of BMP inhibitors like GREM2 and 
Noggin reduces cardiac gene expression and decreases the numbers of 
cardiomyocytes observed in differentiating cultures. Expression data also shows that 
GREM2 and NOGGIN are the two antagonists expressed during the cardiac 
differentiation process. However these assays are unable to distinguish between 
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GREM2 and NOGGIN. Thus future studies that specifically knock out or otherwise 
neutralize GREM2 and NOGGIN are required to establish the necessity for GREM2 in 
cardiac differentiation of human pluripotent stem cells. Such efforts would likely employ 
advanced gene editing techniques such as CRISPR that specifically target GREM2 
(Hockemeyer and Jaenisch, 2016). Cell lines with GREM2 removed from the genome or 
with mutant GREM2 coding sequences substituted for the wild type could be 
differentiated using the protocols described in this work. Alternatively, with our more 
detailed understanding of the residues responsible for binding between GREM2 and 
BMP ligands and how these differ from those found within NOGGIN, engineered BMP 
proteins similar to L51P but that specifically bind and sequester GREM2 could be used 
to obtain similar results. 
This work shows that GREM2 is able to affect both proliferation of cardiac 
progenitor cells and differentiation of cardiomyocytes in differentiating human pluripotent 
stem cells. This molecular switch effect is shown to be unique to GREM2 among other 
BMP antagonists. However it still remains to be determined if this paradigm is employed 
by other signaling pathways and their respective ligands.  
Also remaining to be explored is the mechanism behind the unique molecular 
switch effect of GREM2. The current hypothesis is that this unique effect is 
accomplished via the unique biding properties observed in GREM2:BMP complexes 
and their interactions with BMP receptors (Nolan et al., 2016). GREM2:BMP complexes 
are able to form unique polymeric structures and retain some affinity for BMP and other 
receptors. Each of these possible mechanisms needs to be investigated using 
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pluripotent stem cell differentiation assays to test the hypothesis that these unique 
properites indeed play a role in GREM2’s molecular switch effect.   
As already discussed, in differentiating mouse ES cells and zebrafish, GREM2 
was able to selectively affect atrial cardiomyocyte differentiation at the expense of 
ventricular myocytes. So far this effect has not been observed in differentiating human 
pluripotent stem cells. This does not rule out a role for GREM2 in affecting the type of 
cardiac cells generated during human pluripotent stem cell differentiation. Differentiating 
human pluripotent stem cells are highly sensitive to the concentrations, timing, and 
duration of treatment with exogenous factors or small molecules (Mummery et al., 2012; 
Burridge et al., 2012; Lian et al., 2013). It is possible that a thorough investigation of the 
effect of adjusting treatment duration, concentration, and day of GREM2 treatment will 
reveal an effect on the subtypes of cardiomyocytes generated from human pluripotent 
stem cells. RNA seq analysis of the transcriptome of pluripotent stem cells treated with 
GREM2 vs. controls would also reveal the extent to which GREM2 might affect the 
properties of the cardiomyocytes generated from GREM2 treated cultures. The RT-
qPCR studies reported in this work were able to indicate the degree to which GREM2 
treatment affected specific genes chosen for their well characterized ability to mark 
cardiomyocytes. However the low throughput nature of RT-qPCR makes it impractical to 
sample all known cardiac genes and their regulatory signaling pathways. RNA seq 
allows global profiling of all genes being actively transcribed in a cell population 
(McGettigan, 2013; Mortazavi et al., 2008). Subsequent bioinformatics analysis can 
then be used to look at how GREM2 treatment is affecting the entire complement of 
known cardiac and signaling pathway markers.   
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Appendix A 
Table 1 Amplification primer sequences 
   
Gene Forward Reverse 
ALK3 GGACATTGCTTTGCCATCATA CAGACCCACTACCAGAACTTT 
ALK6 AGTGTCGGGACACTCCCATTC TGAACCAGCTGGCTTCCTCTGTG 
BMP2 ACCCGCTGTCTTCTAGCGT TTTCAGGCCGAACATGCTGAG 
BMP4 GCTGTCAAGAATCATGGACTGTTAT CCTCATAAATGTTTATACGGTGGAA 
BMPR2 AGGTGAAAAGATCAAGAAACGTGTG TCCAGCGATTCAGTGGAGATG 
CERBERUS CATCCAGGGACTCAGATAGTGA GCAGGTCTCCCAATGTACTTCA 
CHORDIN CCCAACACATGCTTCTTCGAG CACCATCAAAATAGCAGCCCT 
GAPDH AAGGTGAAGGTCGGAGTCAAC GGGGTCATTGATGGCAACAATA 
GREM2 ATCCCCTCGCCTTACAAGGA TCTTGCACCAGTCACTCTTGA 
ID2 GCATCCCCCAGAACAAGAAGGTGAG  CGCTTATTCAGCCACACAGTGCTTTG 
ISL1 GCGGAGTGTAATCAGTATTTGGA GCATTTGATCCCGTACAACCT 
KDR GTGATCGGAAATGACACTGGAG CATGTTGGTCACTAACAGAAGCA 
MESP-1 CGCTATATCGGCCACCTGTC GGCATCCAGGTCTCCAACAG 
MYH6 GGGGACAGTGGTAAAAGCAA TCCCTGCGTTCCACTATCTT 
MYL7 GAGGAGAATGGCCAGCAGGAA GCGAACATCTGCTCCACCTCA 
NKX2.5 GCGATTATGCAGCGTGCAATGAGT AACATAAATACGGGTGGGTGCGTG 
NOGGIN ATCGAACACCCAGACCCTATC TCTAGCCCTTTGATCTCGCTC 
ß-ACTIN TGAAGTGTGACGTGGACATC GGAGGAGCAATGATCTTGAT 
T BRY TATGAGCCTCGAATCCACATAGT CCTCGTTCTGATAAGCAGTCAC 
TNNT2 TTCACCAAAGATCTGCTCCTCGCT TTATTACTGGTGTGGAGTGGGTGTGG 
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